|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:MLLT3-SOD2 (FusionGDB2 ID:53978) |
Fusion Gene Summary for MLLT3-SOD2 |
Fusion gene summary |
Fusion gene information | Fusion gene name: MLLT3-SOD2 | Fusion gene ID: 53978 | Hgene | Tgene | Gene symbol | MLLT3 | SOD2 | Gene ID | 4300 | 100129518 |
Gene name | MLLT3 super elongation complex subunit | SOD2 overlapping transcript 1 | |
Synonyms | AF9|YEATS3 | SOD2 | |
Cytomap | 9p21.3 | 6q25.3 | |
Type of gene | protein-coding | ncRNA | |
Description | protein AF-9ALL1-fused gene from chromosome 9 proteinKMT2A/MLLT3 fusionKMT2A/MLLT3 fusion proteinYEATS domain-containing protein 3myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog); translocated to, 3myeloid/lymphoid or mixed-lineage leu | Superoxide dismutase [Mn], mitochondrial | |
Modification date | 20200327 | 20200313 | |
UniProtAcc | P42568 | . | |
Ensembl transtripts involved in fusion gene | ENST00000380338, ENST00000355930, ENST00000429426, ENST00000475957, ENST00000380321, | ENST00000546087, ENST00000538183, ENST00000367055, ENST00000367054, ENST00000444946, ENST00000337404, ENST00000452684, ENST00000535372, | |
Fusion gene scores | * DoF score | 18 X 14 X 11=2772 | 13 X 22 X 6=1716 |
# samples | 25 | 22 | |
** MAII score | log2(25/2772*10)=-3.47092725747513 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(22/1716*10)=-2.96347412397489 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: MLLT3 [Title/Abstract] AND SOD2 [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | MLLT3(20620653)-SOD2(160109274), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | MLLT3 | GO:0045893 | positive regulation of transcription, DNA-templated | 25417107|27105114 |
Hgene | MLLT3 | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 19591803 |
Fusion gene breakpoints across MLLT3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across SOD2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | STAD | TCGA-CD-A48C-01A | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
Top |
Fusion Gene ORF analysis for MLLT3-SOD2 |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
In-frame | ENST00000380338 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
In-frame | ENST00000380338 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
In-frame | ENST00000380338 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000380338 | ENST00000367054 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000380338 | ENST00000444946 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000380338 | ENST00000337404 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000380338 | ENST00000452684 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000380338 | ENST00000535372 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-3CDS | ENST00000355930 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-3CDS | ENST00000355930 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-3CDS | ENST00000355930 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000355930 | ENST00000367054 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000355930 | ENST00000444946 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000355930 | ENST00000337404 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000355930 | ENST00000452684 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000355930 | ENST00000535372 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
In-frame | ENST00000429426 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
In-frame | ENST00000429426 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
In-frame | ENST00000429426 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000429426 | ENST00000367054 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000429426 | ENST00000444946 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000429426 | ENST00000337404 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000429426 | ENST00000452684 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5CDS-intron | ENST00000429426 | ENST00000535372 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-3CDS | ENST00000475957 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-3CDS | ENST00000475957 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-3CDS | ENST00000475957 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000475957 | ENST00000367054 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000475957 | ENST00000444946 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000475957 | ENST00000337404 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000475957 | ENST00000452684 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
5UTR-intron | ENST00000475957 | ENST00000535372 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-3CDS | ENST00000380321 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-3CDS | ENST00000380321 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-3CDS | ENST00000380321 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-intron | ENST00000380321 | ENST00000367054 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-intron | ENST00000380321 | ENST00000444946 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-intron | ENST00000380321 | ENST00000337404 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-intron | ENST00000380321 | ENST00000452684 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
intron-intron | ENST00000380321 | ENST00000535372 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000380338 | MLLT3 | chr9 | 20620653 | - | ENST00000546087 | SOD2 | chr6 | 160109274 | - | 1122 | 480 | 287 | 922 | 211 |
ENST00000380338 | MLLT3 | chr9 | 20620653 | - | ENST00000538183 | SOD2 | chr6 | 160109274 | - | 14359 | 480 | 287 | 922 | 211 |
ENST00000380338 | MLLT3 | chr9 | 20620653 | - | ENST00000367055 | SOD2 | chr6 | 160109274 | - | 1177 | 480 | 287 | 922 | 211 |
ENST00000429426 | MLLT3 | chr9 | 20620653 | - | ENST00000546087 | SOD2 | chr6 | 160109274 | - | 924 | 282 | 98 | 724 | 208 |
ENST00000429426 | MLLT3 | chr9 | 20620653 | - | ENST00000538183 | SOD2 | chr6 | 160109274 | - | 14161 | 282 | 98 | 724 | 208 |
ENST00000429426 | MLLT3 | chr9 | 20620653 | - | ENST00000367055 | SOD2 | chr6 | 160109274 | - | 979 | 282 | 98 | 724 | 208 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000380338 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - | 0.006226519 | 0.9937735 |
ENST00000380338 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - | 0.002717432 | 0.9972825 |
ENST00000380338 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - | 0.004620289 | 0.9953797 |
ENST00000429426 | ENST00000546087 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - | 0.001349269 | 0.9986507 |
ENST00000429426 | ENST00000538183 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - | 0.001388993 | 0.998611 |
ENST00000429426 | ENST00000367055 | MLLT3 | chr9 | 20620653 | - | SOD2 | chr6 | 160109274 | - | 0.001212991 | 0.998787 |
Top |
Fusion Genomic Features for MLLT3-SOD2 |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for MLLT3-SOD2 |
Go to FGviewer for the breakpoints of chr9:20620653-chr6:160109274 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
MLLT3 | . |
FUNCTION: Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA (PubMed:20159561, PubMed:20471948, PubMed:25417107, PubMed:27105114, PubMed:27545619). Specifically recognizes and binds acylated histone H3, with a preference for histone H3 that is crotonylated (PubMed:25417107, PubMed:27105114, PubMed:27545619, PubMed:30374167, PubMed:30385749). Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors (PubMed:25417107, PubMed:27105114, PubMed:27545619). Recognizes and binds histone H3 crotonylated at 'Lys-9' (H3K9cr), and with slightly lower affinity histone H3 crotonylated at 'Lys-18' (H3K18cr) (PubMed:27105114). Also recognizes and binds histone H3 acetylated and butyrylated at 'Lys-9' (H3K9ac and H3K9bu, respectively), but with lower affinity than crotonylated histone H3 (PubMed:25417107, PubMed:27105114, PubMed:30385749). In the SEC complex, MLLT3 is required to recruit the complex to crotonylated histones (PubMed:27105114, PubMed:27545619). Recruitment of the SEC complex to crotonylated histones promotes recruitment of DOT1L on active chromatin to deposit histone H3 'Lys-79' methylation (H3K79me) (PubMed:25417107). Plays a key role in hematopoietic stem cell (HSC) maintenance by preserving, rather than confering, HSC stemness (PubMed:31776511). Acts by binding to the transcription start site of active genes in HSCs and sustaining level of H3K79me2, probably by recruiting DOT1L (PubMed:31776511). {ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948, ECO:0000269|PubMed:25417107, ECO:0000269|PubMed:27105114, ECO:0000269|PubMed:27545619, ECO:0000269|PubMed:30374167, ECO:0000269|PubMed:30385749, ECO:0000269|PubMed:31776511}. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 56_58 | 64.33333333333333 | 569.0 | Region | Inhibitor XL-07i binding |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 149_194 | 64.33333333333333 | 569.0 | Compositional bias | Note=Poly-Ser |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 383_391 | 64.33333333333333 | 569.0 | Compositional bias | Note=Poly-Ser |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 466_469 | 64.33333333333333 | 569.0 | Compositional bias | Note=Poly-Pro |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 1_138 | 64.33333333333333 | 569.0 | Domain | YEATS |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 295_300 | 64.33333333333333 | 569.0 | Motif | Nuclear localization signal |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 106_108 | 64.33333333333333 | 569.0 | Region | Histone H3K9cr binding |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 106_109 | 64.33333333333333 | 569.0 | Region | Inhibitor XL-07i binding |
Hgene | MLLT3 | chr9:20620653 | chr6:160109274 | ENST00000380338 | - | 2 | 11 | 78_80 | 64.33333333333333 | 569.0 | Region | Histone H3K9cr binding |
Top |
Fusion Gene Sequence for MLLT3-SOD2 |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>In-frame_ENST00000380338_ENST00000546087_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(transcript)=1122nt_BP=480nt GAGGCTCGGAGCCCGGGTGTCAGGCGCCACGGCGCATGCTCCGCAATCATCTTCTTTACCCTGGAGCTGCTGCTGCTGCTGCTGCTTTTG CTTTTGGGGCTGAGTTTAATAAGCGAGCGAGCGAGCAAGCGAGCGCGGGGGGAAAAAGGCAGAGAATGTCCGCCATCTACCCTCCGCTCC TGGGCGCGCTCTCATTCATAGCAGCCTCTTCATGAATTACAGCTGAGGGGGGGCGGAGGAGGGGGGGGTACCACACAACACCCCAGCAAA CCTCCGGGCCCCCAGGCATGGCTAGCTCGTGTGCCGTGCAGGTGAAGCTGGAGCTGGGGCACCGCGCCCAGGTGAGGAAAAAACCCACCG TGGAGGGCTTCACCCACGACTGGATGGTGTTCGTACGCGGTCCGGAGCACAGTAACATACAGCACTTTGTGGAGAAAGTCGTCTTCCACT TGCACGAAAGCTTTCCTAGGCCAAAAAGAGGAGATGTTACAGCCCAGATAGCTCTTCAGCCTGCACTGAAGTTCAATGGTGGTGGTCATA TCAATCATAGCATTTTCTGGACAAACCTCAGCCCTAACGGTGGTGGAGAACCCAAAGGGGAGTTGCTGGAAGCCATCAAACGTGACTTTG GTTCCTTTGACAAGTTTAAGGAGAAGCTGACGGCTGCATCTGTTGGTGTCCAAGGCTCAGGTTGGGGTTGGCTTGGTTTCAATAAGGAAC GGGGACACTTACAAATTGCTGCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGG AGCACGCTTACTACCTTCAGTATAAAAATGTCAGGCCTGATTATCTAAAAGCTATTTGGAATGTAATCAACTGGGAGAATGTAACTGAAA GATACATGGCTTGCAAAAAGTAAACCACGATCGTTATGCTGATCATACCCTAATGATCCCAGCAAGATAATGTCCTGTCTTCTAAGATGT GCATCAAGCCTGGTACATACTGAAAACCCTATAAGGTCCTGGATAATTTTTGTTTGATTATTCATTGAAGAAACATTTATTTTCCAATTG >In-frame_ENST00000380338_ENST00000546087_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(amino acids)=211AA_start in transcript=287_stop in transcript=922 MASSCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRGDVTAQIALQPALKFNGGGHINHSIF WTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYL -------------------------------------------------------------- >In-frame_ENST00000380338_ENST00000538183_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(transcript)=14359nt_BP=480nt GAGGCTCGGAGCCCGGGTGTCAGGCGCCACGGCGCATGCTCCGCAATCATCTTCTTTACCCTGGAGCTGCTGCTGCTGCTGCTGCTTTTG CTTTTGGGGCTGAGTTTAATAAGCGAGCGAGCGAGCAAGCGAGCGCGGGGGGAAAAAGGCAGAGAATGTCCGCCATCTACCCTCCGCTCC TGGGCGCGCTCTCATTCATAGCAGCCTCTTCATGAATTACAGCTGAGGGGGGGCGGAGGAGGGGGGGGTACCACACAACACCCCAGCAAA CCTCCGGGCCCCCAGGCATGGCTAGCTCGTGTGCCGTGCAGGTGAAGCTGGAGCTGGGGCACCGCGCCCAGGTGAGGAAAAAACCCACCG TGGAGGGCTTCACCCACGACTGGATGGTGTTCGTACGCGGTCCGGAGCACAGTAACATACAGCACTTTGTGGAGAAAGTCGTCTTCCACT TGCACGAAAGCTTTCCTAGGCCAAAAAGAGGAGATGTTACAGCCCAGATAGCTCTTCAGCCTGCACTGAAGTTCAATGGTGGTGGTCATA TCAATCATAGCATTTTCTGGACAAACCTCAGCCCTAACGGTGGTGGAGAACCCAAAGGGGAGTTGCTGGAAGCCATCAAACGTGACTTTG GTTCCTTTGACAAGTTTAAGGAGAAGCTGACGGCTGCATCTGTTGGTGTCCAAGGCTCAGGTTGGGGTTGGCTTGGTTTCAATAAGGAAC GGGGACACTTACAAATTGCTGCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGG AGCACGCTTACTACCTTCAGTATAAAAATGTCAGGCCTGATTATCTAAAAGCTATTTGGAATGTAATCAACTGGGAGAATGTAACTGAAA GATACATGGCTTGCAAAAAGTAAACCACGATCGTTATGCTGAGTATGTTAAGCTCTTTATGACTGTTTTTGTAGTGGTATAGAGTACTGC AGAATACAGTAAGCTGCTCTATTGTAGCATTTCTTGATGTTGCTTAGTCACTTATTTCATAAACAACTTAATGTTCTGAATAATTTCTTA CTAAACATTTTGTTATTGGGCAAGTGATTGAAAATAGTAAATGCTTTGTGTGATTGAATCTGATTGGACATTTTCTTCAGAGAGCTAAAT TACAATTGTCATTTATAAAACCATCAAAAATATTCCATCCATATACTTTGGGGACTTGTAGGGATGCCTTTCTAGTCCTATTCTATTGCA GTTATAGAAAATCTAGTCTTTTGCCCCAGTTACTTAAAAATAAAATATTAACACTTTCCCAAGGGAAACACTCGGCTTTCTATAGAAAAT TGCACTTTTTGTCGAGTAATCCTCTGCAGTGATACTTCTGGTAGATGTCACCCAGTGGTTTTTGTTAGGTCAAATGTTCCTGTATAGTTT TTGCAAATAGAGCTGTATACTGTTTAAATGTAGCAGGTGAACTGAACTGGGGTTTGCTCACCTGCACAGTAAAGGCAAACTTCAACAGCA AAACTGCAAAAAGGTGGTTTTTGCAGTAGGAGAAAGGAGGATGTTTATTTGCAGGGCGCCAAGCAAGGAGAATTGGGCAGCTCATGCTTG AGACCCAATCTCCATGATGACCTACAAGCTAGAGTATTTAAAGGCAGTGGTAAATTTCAGGAAAGCAGAAGTTAAAGGCAAAATTGTAAA TCAGTCGAGATCGGGTGCCTTCAGGGTGGTATGGCTGTATACCAAAATTGTAAATCACTACATGAAGCTTATATATTGGTTTGGCCTGAA AGGTGAAGTGGGGTAGGCAGGGGGCGGGCTTACAGGTTATGGTGGATTCAAAGACTCCCTGATTTGTGATTGGTTAAGGAAGCAAAGCTT TGTCTAAAAACTTGGGGTCCGCAGAAAGGAACATTAAGGTCTGGCCAGGCCCCTCAGGAAGAAACTGAGAGCAAAGAATGGAGGTCAGAG TTTAGTCCCTGGTGTTCCCCCTTATCTGACGTCTGTGTGAATCCATTTGGTGGGGGTCTGGGTTTCTGAAAAGTAGCTCAGGGGCACGTG TTAAGGATGTCTCTAGGTGACTCTAACTTCCCTGGCTATTGTTTGAAACTGTTATGACCTTCTTGCTTATCAGCTTGCTGGTTTCCTTCT CGGGGCGAGCTGGGTGCCTGGAGTTTTCGGTGAAGGAAACTCAAGATTCTCCTTTATTTCTGTGCTTGTGGGAATCCCCCTGGCACACCC CAAAGAGGGGTCCCTGCTCCGTCTCACAGGGATCTTTTTGTATATTTGGCTTAGCATCATACATTTGCCATGTTGTTTCATCATCTGCCT AATTTACTGTTTTTGAATATTTCATTTGTTTCTAATTGTTACTACAGATAATGCTGGGGTGAGCAACTCTGTGTACATAGGTTTATCTCC TATTGGAATATTTTCTTTATATAGGCGTTTTTTTTTTTTCTTTTTTTTTGGAGACAGAGTCTTGCTCTGTTGCCCAGGCTGGAGTGCAGT GGCGCGACCGGAGCTCACTGCAACCTCCACTTCCCGGGTTCAAGTGATTGTCCCACCTCAGCCTCCTGAATAGCTGGGATTACAGGTGCA TGCTACCATGCCTGGCTACTTTTTGTATTTTTAGCAGAGACAGGGTTTCACCATGTTGGCCAGGGTGGTCTCGAACTCCTGACCTCAAGT GATCCGTCTGGCTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGCACCTGGCCTATATAGGCTTTTTTCTTAAACCTATTT AGTAATGTTTTCCCAAGTTTATTTTTTATTTTTAATTTTTTCCCCAAGTTTATTTTTCTATTTTTTTTTCATGGAAAAATGGGGTAACTT AGCAGTTTCAATATTGAAGACTGAAGTTTAAAAAAAATTTAAATTCAAGGTACTTTTAAAATTCAGTTAGAAAAGTAGGCTTTAAAAATT ATTAGAGACAAGAGTACCAAAGCGGTGTGTGTATGTGTGTGTGTGTATGCATGCTTGTGGATTGGAAAAACTTTGGAGACTGATTACTTT TCATTATATATGTGTCACAGTGAAACAGCTTTTATGTGTCATGTAAGATTACTGCTTGCCTCTCTAAGGAAGGTCGTGACTGTTTAAATA GACGGGCAAGGTGGAACCTTTTGAAAGATGAGCTTTTGAATATAAGTTGTCTGCTAGATCATGGTTTGTATTGAACTAACAAGGTTTGCA GATCTGCTGACTTATATAAAGCTTTTTGATTCCTACTAAGCTTTAAGATTTAAAAAATGTTCAATGTTGAAATTTCTGTGGGGCTCTATT TTTGCTTTGGCTTTCTGGTGAGAGAGTGAGGAAGCATTCTTTCCTTCACTAAGTTTGTCTTTCTTGTCTTCTGGATAGATTGATTTTAAG AGACTAAGGGAATTTACAAACTAAAGATTTTAGTCATCTGGTGGAAAAGGAGACTTTAAGATTGTTTAGGGCTGGGCGGGGTGACTCACA TCTGTAATCCCAGCACTTTGGGAGGCCAAGGCAGGCAGAACACTTGAAGGAGTTCAAGACCAGCGTGGCCAACGTGGTGAAACCCTGTCT CTACTAAAAATACAAAAATTGTTTAGCTCTGTTTTTCATAATAGAAATAGAAAAGGTAAAATTGCTTTTCTTCTGAAAAGAACAAGTATT GTTCATCCAAGAAGGGTTTTTGTGACTGAATCAGCAGTGCCTGCCCTAGTCATAGCTGTGCTTCAAAAACCTCAGCATGATTAGTGTTGG AGCAAAACAAGGAAGCAAAGCAAATACTGTTTTTGAAATTCTATCTGTTGCTTGAACTATTTTGTAATAATTAAACTTTGATGTTGAGAA ATCACAACTTTATTGTACACTTCATTGCAACTTGAAATTCATGGTCTTAAAGTGAGATTTGAATTTCTATTGAGCGCCTTTAAAAAAGTA ATACCAAACCATAAAGTTAAAATCTATGTATATTGAGTCATATCTAAAACCACGTATAAACATAAATTGTATTTCCTGTTTTAATTCCAG GGGAAGTACTGTTTGGGAAAGCTATTATTAGGTAAATGTTTTACAAATTACTGTTTCTCACTTTCAGTCATACCCTAATGATCCCAGCAA GATAATGTCCTGTCTTCTAAGATGTGCATCAAGCCTGGTACATACTGAAAACCCTATAAGGTCCTGGATAATTTTTGTTTGATTATTCAT TGAAGAAACATTTATTTTCCAATTGTGTGAAGTTTTTGACTGTTAATAAAAGAATCTGTCAACCATCAAAGAGGTCTGCATTATGCTTGC ATGTCAAAAACTTTAAAAATCCTATAATCTTCTGTCATTTTCACTGAGTTTCCATGGGAAAGGAATAGTAAATAATGGGTAGTTGAAATA TTACTCTTAAGACCAAGACCTGTATCTCCAGTCATATCTGTAATAACATCATCTGATAACCTAAAAGCATAGTATTAGGGATATACGACA AAACCAAAGTGTTTTTGCTGTTGTCACATACCACTCAATACTTTTACACCAGGTTGTCCAGTGGACACCAGCTGGATGTCCTATAATTCA ATTCTGACACTGTCTACCTGGAATTGGAGTCAGATCCCACAGGTGGAGGGCTCAGCCCACAAGACTGCCCCCACTCCAGATACCAATCGC AAGTCCCTATACTTCTGACTGGCTATAAAGTGGGGTTCCCGTGACCCTTTCCTTGGTTTTGATTTATTTGCTAGAGCAGCTCCCAGAACA CAGAGAAACACTCTACTTATGTTTACCCATTTTTAATTTTATTACTTTATTAAAACTACATATTGGTTACAATACTAATTTATTGTAAAG GATATTTCATTTATTTATTTTTTTATTTAGAGATGGAGTCTCACTGTGTCACCCAGGCTGGAGTGCGGTGGCACAGTCTCAACTCACTGC AACCTCCACCTCCTGAGTTCAAGCGATTCTCATGCCTCAGCCTCCCAAGTAGCTGGGATTACAAGTGTGCACCACCATGCCCAGCTAATT TTTGTATTTTTAGTAGAGATGGGGTTTCACTCTGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGTCATCCACCCACCTCAGCCTCC CAAAGTGCTGAGATTACAGGTGTGAGCCATTGCCTCTGGCTTGTAAAGGATATTTCAAAGAATACAGATGAACAGCCAGATGGAAGAGAT GCACAGGGCAAGGCATGTGGGAAGGGGTATGGAGCTTTCATGCTCTCTCCACGTCATCAGCTACCCAGAAGCTCATCTGGACCCCGACCC TTTGGGGTTTTACGGAGGCTTCATTATGTCAGCATTACCATTGGCAATTGGCGATTAACTCAACCTTCAGCCTCTCTCCCCTTTCTGGAG GTTGGGGGTTGAGGCTGGGAGTCCAAACCCTCCAATCTTGCCTTGGTCTTTCTGGTAAGCAGCCCCCCGTCCTGAAGCTACCTAGAGGCT CCCAGCCACCAATCATTTCATTGGCAAACCAAAGATACTTCAAGGGGTTTAGGAGCCAAGAGACCAAGCAAGGATTGAGACAATATATAT ATTTCTTATAAATAACATGATCACAAATAGTATTTTATATATTTCTCATAATAGCTGGTTGTGGTTACTCACACCTATCATCCCAGCTAC TAAGAAGCTAAGGCAGGAGGATCACAGGCCCAGGAGTTTGCAGCTGTAGTGAGCTATGATTGTGCTACTGCACTCCAGCCTGGGTGACAG TGTGAGACCCTGTCTCTTAAAGTTCTTGTAACATCTTAGAACATTAACCAACCACAGATTATTGCCTTAACTCTGAAAAATAAAGTAATC ATACTTTTACAAGATGTATTTTACATAAAGTTCTGGTGATATTTTACTCTGGTCATTGGAATATAGGAGCTTACCACCTGGTACCACTCT TCCTAAAGTGGTATACTATTTGGTATAGTACTGGCATACTATTTGGAAAGGGATGTGAAGTTGGCATGACCTGTCTAGGGTGAAGTCATG CTGTCTGCTATTCATTGTGGGCTTTACAGTAATGAGAGTGCTTCTGTTGTCAAGATGCTTCTGGGACACGTTAAAAAAAATTTAAGATTT CTCAGTTTGTGAAAAGGAAGGAGCACGAATGCTTTCAAGTTCCTATGACATGCTAGTCATCTTTCAGTGTGTCCCATTGTTGCACCCAGT AGTCTCGATGCCCAGCGTCACGGTGATTCCAAGTTTGCCTCTCTGCCCACTATAATTTGTGCTCCATGAAGTCCCAGGACATGAGGTTCT TGTTCATTTGTGCGTCTGGGCCCATATCCAAATATTAAACAATGTGACTTAATGTATTTATCATATTGTAAATATGGGTATCCCCAAGGC TCAGAAGTTAACACAGCATATCCACAGAGAGGTTTGACAGCATGGCTGTGGTGACTGGGAAGGCCTTATGCTTGCTCCTCCTTCTGCTGC TTGCCTTTGTGTGGGCATGGAAAGAACATTGAATTAGGTACTGGAAGACCTGGGTCCTGGTCTTGGAGATTTTACCAGAGCACCTGTGGG ATATTGGTCAAGATGCCTGGTTTTAGTCCTGCTCCTTTGCTGTGAAAGAGGATCTTAAGGTGCCAACTCTGGCATTTTATTTTTTACTTA TTTATTTTTAAATTATACTTTAAGTTCTAGGGTACATGTGTACAACATGCAGGTTTGTTACATGTATACATGTGCCATGTTGGTGTGCTG CACCTATTAACTCGTCATTTACATTAGGTATATCTCCTAATGCTATCCCTCCCCCTTCTCCCCACCCCTCGACAGGCCCCGGTGTGTGAT GTTCCCCTTCCTGTGTCCAAGTGTTCTCATTGTTCAATTCCCATCTATGAGTGAGAACATGCGGTGTTTGTTTTTTTGTCCTTGGAATAG TTTGCTGAGAAGGATGGTTTCCAGCTTCATCCATGTCCCTATAAAGGACATGAACTCTTCCTTTTTTATGGCTGCATAGTATTCCATGGT GTATATGTGCCACATCTTCTTAAACCAATCTATCATTGATGGACATTTGGGTTGGTTCCAAGTCTTTGCTATTGTGAACAGTGCCACAAT AAATATACGTGTGCATGTGTCTTTATAGCAGCATGATTTATAATCCTTTGGGTATATACCCAGTAATGGGATGGCTGGGTCAAATGGTAT TTCTAGTTCTAGATCCCTGAGGAATCGCCACACTGTCTTCCACAATGGTTGAACTAGTTTACAGTCCCACCACCAGTGTAAAAGTGTTCC TATTTCTCCACATCCTCTCCAGCACCTGTTGTTTCCTGACTTTTTAATGATTGACATTCTAACTGGTGTGAGATGGTATCTCATTGTGGT TTTGATTTGCATTTCTCTGATGGCCCATGATGATGAGCATTTTTTTCATGTGTCTGTTGGATGCATGGATGTCTTCTTTTGAGAAGTGTC TCTTCATATCCTTCACCTACTTTTTGATGGGGTTTGTTTTTTTCTTGTAAGTTTGTTTGAGTTCCTTGTAGATTCTGGATATTAGCCCTT TGTCAGATGAGTAGATTGCAAAAATTTTCTCCCATTTTGTAGGTTGCCTGTTCACTCTGATGGTAGTTTCTTTTGCTGTGCAGAAGCTCT TGAGTTTAATGAGATCCCATTTGTCAATTTTGGCTTCTGTTGCCATTGCTTTTGGTGTTTTAGACATGAAGTCCTTGCCCATGCCTGTGT CCTGAATGGTACTGCATAGGTTTTCTTCTAGGGTTTTTATGGTTTTAGGTCTAACATTTAAGTCTTTAATCCATCTTGAATTAATTTTTG TATAAGGTGTAAGGAAGGGATCCAGTTTCAGCTTTCTACATGTGGCTAGCCAGTTTTCCCAGCACCATTTATTAAATAGGGAATCCTTTC CCCATTTCTTGTTTTTGTCAGGTTTCTCAAAGATCAGATAGTTGTAGATGTGTGGTATTATTTCTGAGGGCTCTGTTCTGTTCCATTGGT CTATATCTCTGTTTTGGTACTAGTACCATGCTGTTTTGGTTACTGCAGCCTTGTAGTATAGTTTGAAATCAGGTAGCGTGATGCCTCCAG CTTTGTTCTTTTGGCTTAGGATCGTTTTGGCAGTGCAGGCTCTTTTTTGGTTCCACATGAACTTTAAAGTAGTTTTTTCCAATTCTATGA AGAAAGTCATGGGTAGCTTGATGGGGATGGCATTGAATCTATAAATTACCTTGGGCAGTATAGCCATTTTCACGATATTGATTCTTCCTA TCCATGAGCATGGAATGTTCTTCCATTTGTTTGTGTCCTCTTTTATTTCCTTGAGCAGTGGTTTGTAGTTCTCCTTGAAGAGGTCCTTCA CATCCCTTGTAAGTTGGATTCCTAGGTATTTTATTCTCTTTGAGGCAGTTGTGAATGGGAGTTCACTCATGATTTGGCTCTCTGTTTGTC TGTTGTTGGTGTATAAGAATGCTTGTGATTTTTGCACATTGATTTTGTATCCTGAGATTTTGCTGAAGTTGCTTATCAAATTAAGGAGAT TTTGGGCTGAGATGATGGGGTTTTCTAAATATAAAATCATGTCATCTGCAAACAGGGACAATTTGACTTCCTCTTTTCCTTATTGAATAC CCTTTATTTCTTTCTCCTGCCTGATGGCCCTGGCCAGAACTTCCAACACTATGTTGAATAGGAGTGGTGAGAGAGGGCATCCCTGTCTTG TGCCAGTTTTCAAAGGGAATGCTTCCAGTTTTTGCCCATTCAGTCTGATATTGGCTGTGGGTTTGTCATAGATAGCTCTTATTATTTTGA GATATGTCCCATCAATACCTAATTCATTGAGAGTTTTTAGCATGAAGGGCTGTTGAATTTTGTCCAAGGCCTTTTCTGCATCTGTTGAGA TAATCATGTGGTTTTTGTCTTTGGTTCTGTTTATATGCTGGATTACTTTTATTGATTTGTGTATGTTGAACCAGCCTTGCATCCCAGGGA TGAAGCCCACTTGATCATGGTGGATAAGCTTTTTGATATGCTGCTGGATTCAGTTTGCCAGTATTTTATTGAGGATTTTTGCATTGATTT TCATCAGGGATATTGGTCTAAAGTTCTCTTTTTTTGTTATGTCTCTGCCAGGCTTTGGTATCAGGATGATGCTGGCTTCATAAAATGAGT TAGGGAGGATTCCCTCTTTTTCTATTGATTGGAATAGTTTCAGAAGGAATGGTACCAGCTCTTCCTTGTACCTCTGGTAGAATTCGGCTG TGAATCCATCTTGTCCTGGACTTTTTTTGGTTGGTAGGCTATTAATTATTGCCTCAATTTCAGAGCCTGTTATTGGTCTATTCAGGGATT AAACTTCTTCCTGGTTTAGTTTTGAGAGGGTGTATGTGTCCAGGAATTTATCTATTTCTTCTAGATTTTCTAGTTTATTTGCATAGAGGT GTTTATAGTATTCTCTGTGTACTCTGTATTTCTGTGGGATTGGTGGTGATATCCACTTTATCATTTTTTATTGCATTTATTTGATTCTTC TCTCTTTTCTTGTTTATTAGTCTTGCTAGCGGTCTATCAATTGTGTTTATCTTTTCAAAAAACCAGCTCCTGGATTCATTCATTTTTTGA AGGTTTTTTTGTGTCTCTGTCTCCTTCAGTTCTGCTCTGATCTTAGTTATTTCTTGTCTTCTGCTAGCTGTTGAATGTGTTTGCTCTTGC TTCTCTAATATTTTTAATTGTGATGTTAGAGTGTCAATTTTAGATCTTTCCTGCTTTCTCTTGTGGGCACTTAGTGCTGTAAATTTCCCT CTACACACTGCTTTAAATGTGTCCCAGAGATTCTGGTATGTTGTGTCTTTGTTCTCGTTGGTTTCAAAGAACATCTTTATTTCTGCCTTC ATTTTGTTATGTACCCAGTAGTCATTCAGGAGCAGGTTGTTCAGTTTCCATGTAGCTGAGTGGTTTTGAGTGAGTTTCTTAATCCTGAGT TCTAGTTTGATTGCACTGTGGTCTGAGACAGTATGTTATAATTTCTGTTCTTTTACATTTGCTGAGGAGTGCTTTACTTCCAACTATGTG GTCAATTTTGGAATAGGTGCGATGTGGTGCTGAGAAGAATGTATATTCTGTTGATTTGGGGTGGAGAGTTCTGTAGATGTCTATTAGGTC TGCTTGGTGCAGAGCTGAATTCAATTCCTGGATATCCTTGTTAACTTTCTGTCTCGTTGATCTGTCTAATATTGACAGTGGGGTGTTAGA GTCTCCCATTGTTATTGTGTGGGAGTCTAAATCTCTTTGTAGGTCTCTAAGGACTTGGTTTATGAATCTGGGTGCTCCTGTATTGGGTGC ATATATATTTAAGATAGTTAGCTCTTCTTGTTGAATTGATCCCTTTACTATCATGTAATGGCCTTCTTTGTCTCTTTTGATCTTTGTTGG TTTAAAGTCTGTTTTATCAGAGACTAGGATTGCAACCCCGGCCTTTTTTTTTGTTTTCCGTTTGCTTGGTAGATCTTCCTCCATCCTTTT ATTTTGAGCCTATGTGTGTGTGTCTCTGTACGTGAGATGGGTTTCCTGAATACAGCACCCTGATGGGTCTTGACTCTTTATCCAGTGTGC CAGTCTGTGTCTTTTAATTGGAGCATTTAGCCCATTTACATTTAAGGTTAATATTGTTATGTGTGAATTTGATCCTGTCACTAGGATGTT CACTGGTTATTTTGCTCGTTAGTTGATGCAGTTTCTTCCTAGCCTCAATGGTCTTTACAATTTGGCATGTTTTTGCAGTGGCTGATACTG GTTGTTCCATTCCATGTTTAGTGCTTCCTTCAGGAGCTCTTGTAAGGCAGGCCTGGTGGTGACAAAATCTCTCAGCATTTGCTTGTTTGT AAAGGATTTTATTTCTCCTTCACTTATGAAGCTTAGTTTGGCTGGATATGAAATTCTGGGTTGAAAATTCTTTTCTTCAAGAACGTTGAA TATTGACCCCCACTCTCTTCTGGCTTGTAGAGTTTCTGCTGAGAGATCAGCTGTTAGTCTGATGGGCTTCCCTTTGTGGGTAACCCGACC TTTCTCTCTGGCTGCCCTTAACATTTTTTCCTTCATTTCAACTTTGGTGAATCTGACAATTATGTGTCTTGGAGTTGCTCTTCTCGAGGA GTATCTTTGTGGCGTTCTCTGTATTTCCTGAATTTGAATGTTGTCCTCCCTTGCTAGATTGGGGAAGTTCTCCTGGATAATATCCTGCAG AGTGTTTTCCAGCTTGGTTCCATTCTCCCCGTCACTTTCAGGTACACCAATCAGACGTAGATTTGGTCTTTTCACATAGTCCCATATTTC TTGGAAGCTTTGTTCGTTTCTTTTTACTCTTTTTTCTCTTAACTTCTCTTCTCACTTCATTTCATTCATCTGATCTTCAATCACTGATAA CCTTTCTTCCAGTTGATCGAATTGGCTACTGAAGCTTGTGCATTCGTCACGTAGTTCTCATGCCATGGTTTTCAGCTCCATCAGGTCATT TAAGGACTTCTCTATGCTGGTTATTCTAGTTAGCCATTTGTCTAATCTTTTTTCAAGGTTTTTAGGTTCTTTGTGATGGGTTCGAACTTC CTCTTTTAGCTTGGAGAAGTTTGATCATCTGAAGCCTTCTTCTCTCAACTCGTCAAAGTCATTCTCCGTCCAGCTTTGTTCTGTTGCTGG CAAGGAGCTATGTTCCTTTGGAGGGGGAGAGGCGCTCTGATTTTTAGAATTTTCAGCTTTTCTGCTCTGTTTTTTCCCCATCTTTGTGGT TTTATCTACCTTTGGTCTTTGGTGATGGTGATGTGCAGATGGGGTTTTGGTGTGGATGTCCTTTCTGTTTGTTAGTTTTCCTTCTAACAG TCAGGACCGCCAGCTGCAGGTCTGTTGGAGTTTGCTGGACGTCCACGCCAGACCCTGTTTGCCTGGGTATCACAGTGGAGGCTGTAGAAC AGCGAATATTGCTGAACAGCAAATGTTGCTGCCTGATCATTCCTCTGGAAGCTTCATCTCAGAGGGGTACCCGGCCATGTGGGGTGTCAG TCTGCCCCTACTTGGGGGTGCCTCCCAGTTAGGCTACTCGGGGGTCAGGGACTCACTTGAGGAGGCAGTCTCTCCGTTCTCAGATCTCAA ACTCTGTGCTGGGAGAACCACTGGTCTCTTCAAAGCTGTCAGACAGGGACATTGAAGTCTGCAGAGATTTCTGCTGCCTTTTGTTCGGCT ATGCCATGCCCCCAGAGGTGGAGTCTACAGAGGCAGGCAGGCAGGCCTCCTTGAGCTGCAGTGGGCTCCACCTAGTTCGAGCTTCCCGGC TGCTTTATTTACCTACTGAAGCCTCAGCAATGGTGGGCTCCCCTCCCCTAGCCTCACTGCCACCTTGCAGTTCGATCTCAGACTGCTGTG CTAGCAATGAGCAAGGCTCCATGGGCGTGGGACCCTCCGAGCTAGGCACAGGATATAATCTCCTGGTGTGCCGTTTGCTAAGACCATTGG AAAAACGCAGTATTAGGGTGGGAGTGACCCAATTTTCCAGGTGCCGTCTGTCACAGCTTCCCTTGGCTAGGAAAGGGAATTCCCTGACCC CTTGCCTTCCCGGGTGAGGCCATGCCTTGCCCTGCTTCAGCTCATGCTCAGTGGGCTGCACCCACCGTCCTACACCCACTGTCCAACAAG CCCCAGTGAGATGAACCTGGTACCTCAGTTGGAAGTGCAGAAATCACCTGTCTTCTGCGTCGCTCACGCTGGGAGCTGTAGACTGGAGCT GTTCCTATTCGGCCATCTTGGAACCCAACCCAAGTCTGGCATTTTTTGGTTTTCTCTGTGTATTGACTATGATTATAGAGGATAAATGGA TATTGATATTATTAAATCGTCATTTACAGAAGGCACACAACTTATATCCTTTAAACAAAGTTCTCCAACCAGTAGGGTATACTTGCTGGT AGTGCTTACAGCTGCCACCATTCTTCACTGGGGCTCAGAGTGGATGCCTGGAGGAAAAAAACAAATGAATCTTTTAGCTCCTAGTTACTG TTAGCATTTTTACCAGAAAACAATTTAAAAAATGACACAAGTAAGTCTTCACCTATCAAGGCTGAGTGTGGTGGCCTATACTTGTAATCT CTGTGCTTTGGGAGGCCAACGCAGGAGGATCTCTTGAGTCCAGGAGTTTGAGACCAGCCTGGGCAACAAAGCAAGACCCCATCTCTACAG AAAGTTAAAATTTAGCTGGGCATGCTGGCACATCCCTATAGTCCCAGCTACTTGAGAGGCTGAGTTGGGAGGATCCCTTGAGGTCATGAG TTGGAGTCTACAGTGAGCTGTGATTACAGTGTGAGTCTACACTGCACTCCAGTCTGGGTGAAAGAGATCCTGTCTCTCAAAAAACAAGTG ATTCTCCTGGGAAGAGATTTGTTTAAAAAGTCTGCACCTCTATTGATGATAACTTTGAATGTAAATGGATTAAATTCTCCCACTTAAAAG ATATAGATTGACTGAATGGATTAAAAACCACCATCATGACTCGACTGTATGCTGCCTACAAGAAACCTCACCTGTAAAGACAGGCCAAAA GTGAAGGTATGGAGAAAGATATTGCATACAAATGGAAGCCAAAAAAGAGCAGAAATAACTATACTTACATGAGATAAAATAGACTTTAAG TCAAAAACTGTAAAAAGAAAAGTCATTATGTAATGAAACAAGGATCAATTCATGCAAGATATAATCATATTTTTTTATTAAGAAAATTTT TTTGTAGAGATGGGGTTATGCTATGTTGCCTGGCTAGTCTCAAACTCTGGGTCTCAAAGCAGTCCTCCTGCTTTGGCCTCCTAAGGTGCT GGGATTATAGGCATGAGCCACTGTGCCAGGCCTGAGGATATTATCATTATAAATATATATGTACCCCACACTGGATGACCCAGATATAAA GCAAATATTATTAGATTTAAAGGGAGAAATAGACTCTAATACAATAGTAGTTGAGGACTTCACTCTACTCTCAGCATTGGACAGATTTTC TAGACATAAAACCAATAAATATTGGATTTAAATTGCACTTTACACCAAATGGACCTGACATTTACAGAACATTCTAATAGGTGCAGAACA CTCTAATAGCTGCAGAACACACGTTCTTTTCATCAGCACATGGAACATTCACCAGACTAGTTCTGGAACCCACTTCCTGCCTTAGTGTTC TTTCCACCACAGTGCATGATAATTCCGACAGAACGCCTTTTATTTGTACCTTATTAGTTGTAGGGGGAAAGCTTTTTCATGTACAAAAAT >In-frame_ENST00000380338_ENST00000538183_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(amino acids)=211AA_start in transcript=287_stop in transcript=922 MASSCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRGDVTAQIALQPALKFNGGGHINHSIF WTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYL -------------------------------------------------------------- >In-frame_ENST00000380338_ENST00000367055_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(transcript)=1177nt_BP=480nt GAGGCTCGGAGCCCGGGTGTCAGGCGCCACGGCGCATGCTCCGCAATCATCTTCTTTACCCTGGAGCTGCTGCTGCTGCTGCTGCTTTTG CTTTTGGGGCTGAGTTTAATAAGCGAGCGAGCGAGCAAGCGAGCGCGGGGGGAAAAAGGCAGAGAATGTCCGCCATCTACCCTCCGCTCC TGGGCGCGCTCTCATTCATAGCAGCCTCTTCATGAATTACAGCTGAGGGGGGGCGGAGGAGGGGGGGGTACCACACAACACCCCAGCAAA CCTCCGGGCCCCCAGGCATGGCTAGCTCGTGTGCCGTGCAGGTGAAGCTGGAGCTGGGGCACCGCGCCCAGGTGAGGAAAAAACCCACCG TGGAGGGCTTCACCCACGACTGGATGGTGTTCGTACGCGGTCCGGAGCACAGTAACATACAGCACTTTGTGGAGAAAGTCGTCTTCCACT TGCACGAAAGCTTTCCTAGGCCAAAAAGAGGAGATGTTACAGCCCAGATAGCTCTTCAGCCTGCACTGAAGTTCAATGGTGGTGGTCATA TCAATCATAGCATTTTCTGGACAAACCTCAGCCCTAACGGTGGTGGAGAACCCAAAGGGGAGTTGCTGGAAGCCATCAAACGTGACTTTG GTTCCTTTGACAAGTTTAAGGAGAAGCTGACGGCTGCATCTGTTGGTGTCCAAGGCTCAGGTTGGGGTTGGCTTGGTTTCAATAAGGAAC GGGGACACTTACAAATTGCTGCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGG AGCACGCTTACTACCTTCAGTATAAAAATGTCAGGCCTGATTATCTAAAAGCTATTTGGAATGTAATCAACTGGGAGAATGTAACTGAAA GATACATGGCTTGCAAAAAGTAAACCACGATCGTTATGCTGATCATACCCTAATGATCCCAGCAAGATAATGTCCTGTCTTCTAAGATGT GCATCAAGCCTGGTACATACTGAAAACCCTATAAGGTCCTGGATAATTTTTGTTTGATTATTCATTGAAGAAACATTTATTTTCCAATTG TGTGAAGTTTTTGACTGTTAATAAAAGAATCTGTCAACCATCAAAGAGGTCTGCATTATGCTTGCATGTCAAAAACTTTAAAAATCCTAT >In-frame_ENST00000380338_ENST00000367055_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(amino acids)=211AA_start in transcript=287_stop in transcript=922 MASSCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRGDVTAQIALQPALKFNGGGHINHSIF WTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYL -------------------------------------------------------------- >In-frame_ENST00000429426_ENST00000546087_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(transcript)=924nt_BP=282nt ATATTTCAGCCGCCGCCGCCGGGAGCTGCGGGCACAGTCCGGGGACGCGGCGAGCAGCCTCGGCGGCCGCACCTCCGCAAAGCGCCGCGG CCGCTACGATGTGTGCCGTGCAGGTGAAGCTGGAGCTGGGGCACCGCGCCCAGGTGAGGAAAAAACCCACCGTGGAGGGCTTCACCCACG ACTGGATGGTGTTCGTACGCGGTCCGGAGCACAGTAACATACAGCACTTTGTGGAGAAAGTCGTCTTCCACTTGCACGAAAGCTTTCCTA GGCCAAAAAGAGGAGATGTTACAGCCCAGATAGCTCTTCAGCCTGCACTGAAGTTCAATGGTGGTGGTCATATCAATCATAGCATTTTCT GGACAAACCTCAGCCCTAACGGTGGTGGAGAACCCAAAGGGGAGTTGCTGGAAGCCATCAAACGTGACTTTGGTTCCTTTGACAAGTTTA AGGAGAAGCTGACGGCTGCATCTGTTGGTGTCCAAGGCTCAGGTTGGGGTTGGCTTGGTTTCAATAAGGAACGGGGACACTTACAAATTG CTGCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGCTTACTACCTTC AGTATAAAAATGTCAGGCCTGATTATCTAAAAGCTATTTGGAATGTAATCAACTGGGAGAATGTAACTGAAAGATACATGGCTTGCAAAA AGTAAACCACGATCGTTATGCTGATCATACCCTAATGATCCCAGCAAGATAATGTCCTGTCTTCTAAGATGTGCATCAAGCCTGGTACAT ACTGAAAACCCTATAAGGTCCTGGATAATTTTTGTTTGATTATTCATTGAAGAAACATTTATTTTCCAATTGTGTGAAGTTTTTGACTGT >In-frame_ENST00000429426_ENST00000546087_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(amino acids)=208AA_start in transcript=98_stop in transcript=724 MCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRGDVTAQIALQPALKFNGGGHINHSIFWTN LSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYK -------------------------------------------------------------- >In-frame_ENST00000429426_ENST00000538183_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(transcript)=14161nt_BP=282nt ATATTTCAGCCGCCGCCGCCGGGAGCTGCGGGCACAGTCCGGGGACGCGGCGAGCAGCCTCGGCGGCCGCACCTCCGCAAAGCGCCGCGG CCGCTACGATGTGTGCCGTGCAGGTGAAGCTGGAGCTGGGGCACCGCGCCCAGGTGAGGAAAAAACCCACCGTGGAGGGCTTCACCCACG ACTGGATGGTGTTCGTACGCGGTCCGGAGCACAGTAACATACAGCACTTTGTGGAGAAAGTCGTCTTCCACTTGCACGAAAGCTTTCCTA GGCCAAAAAGAGGAGATGTTACAGCCCAGATAGCTCTTCAGCCTGCACTGAAGTTCAATGGTGGTGGTCATATCAATCATAGCATTTTCT GGACAAACCTCAGCCCTAACGGTGGTGGAGAACCCAAAGGGGAGTTGCTGGAAGCCATCAAACGTGACTTTGGTTCCTTTGACAAGTTTA AGGAGAAGCTGACGGCTGCATCTGTTGGTGTCCAAGGCTCAGGTTGGGGTTGGCTTGGTTTCAATAAGGAACGGGGACACTTACAAATTG CTGCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGCTTACTACCTTC AGTATAAAAATGTCAGGCCTGATTATCTAAAAGCTATTTGGAATGTAATCAACTGGGAGAATGTAACTGAAAGATACATGGCTTGCAAAA AGTAAACCACGATCGTTATGCTGAGTATGTTAAGCTCTTTATGACTGTTTTTGTAGTGGTATAGAGTACTGCAGAATACAGTAAGCTGCT CTATTGTAGCATTTCTTGATGTTGCTTAGTCACTTATTTCATAAACAACTTAATGTTCTGAATAATTTCTTACTAAACATTTTGTTATTG GGCAAGTGATTGAAAATAGTAAATGCTTTGTGTGATTGAATCTGATTGGACATTTTCTTCAGAGAGCTAAATTACAATTGTCATTTATAA AACCATCAAAAATATTCCATCCATATACTTTGGGGACTTGTAGGGATGCCTTTCTAGTCCTATTCTATTGCAGTTATAGAAAATCTAGTC TTTTGCCCCAGTTACTTAAAAATAAAATATTAACACTTTCCCAAGGGAAACACTCGGCTTTCTATAGAAAATTGCACTTTTTGTCGAGTA ATCCTCTGCAGTGATACTTCTGGTAGATGTCACCCAGTGGTTTTTGTTAGGTCAAATGTTCCTGTATAGTTTTTGCAAATAGAGCTGTAT ACTGTTTAAATGTAGCAGGTGAACTGAACTGGGGTTTGCTCACCTGCACAGTAAAGGCAAACTTCAACAGCAAAACTGCAAAAAGGTGGT TTTTGCAGTAGGAGAAAGGAGGATGTTTATTTGCAGGGCGCCAAGCAAGGAGAATTGGGCAGCTCATGCTTGAGACCCAATCTCCATGAT GACCTACAAGCTAGAGTATTTAAAGGCAGTGGTAAATTTCAGGAAAGCAGAAGTTAAAGGCAAAATTGTAAATCAGTCGAGATCGGGTGC CTTCAGGGTGGTATGGCTGTATACCAAAATTGTAAATCACTACATGAAGCTTATATATTGGTTTGGCCTGAAAGGTGAAGTGGGGTAGGC AGGGGGCGGGCTTACAGGTTATGGTGGATTCAAAGACTCCCTGATTTGTGATTGGTTAAGGAAGCAAAGCTTTGTCTAAAAACTTGGGGT CCGCAGAAAGGAACATTAAGGTCTGGCCAGGCCCCTCAGGAAGAAACTGAGAGCAAAGAATGGAGGTCAGAGTTTAGTCCCTGGTGTTCC CCCTTATCTGACGTCTGTGTGAATCCATTTGGTGGGGGTCTGGGTTTCTGAAAAGTAGCTCAGGGGCACGTGTTAAGGATGTCTCTAGGT GACTCTAACTTCCCTGGCTATTGTTTGAAACTGTTATGACCTTCTTGCTTATCAGCTTGCTGGTTTCCTTCTCGGGGCGAGCTGGGTGCC TGGAGTTTTCGGTGAAGGAAACTCAAGATTCTCCTTTATTTCTGTGCTTGTGGGAATCCCCCTGGCACACCCCAAAGAGGGGTCCCTGCT CCGTCTCACAGGGATCTTTTTGTATATTTGGCTTAGCATCATACATTTGCCATGTTGTTTCATCATCTGCCTAATTTACTGTTTTTGAAT ATTTCATTTGTTTCTAATTGTTACTACAGATAATGCTGGGGTGAGCAACTCTGTGTACATAGGTTTATCTCCTATTGGAATATTTTCTTT ATATAGGCGTTTTTTTTTTTTCTTTTTTTTTGGAGACAGAGTCTTGCTCTGTTGCCCAGGCTGGAGTGCAGTGGCGCGACCGGAGCTCAC TGCAACCTCCACTTCCCGGGTTCAAGTGATTGTCCCACCTCAGCCTCCTGAATAGCTGGGATTACAGGTGCATGCTACCATGCCTGGCTA CTTTTTGTATTTTTAGCAGAGACAGGGTTTCACCATGTTGGCCAGGGTGGTCTCGAACTCCTGACCTCAAGTGATCCGTCTGGCTCAGCC TCCCAAAGTGCTGGGATTACAGGTGTGAGCCACTGCACCTGGCCTATATAGGCTTTTTTCTTAAACCTATTTAGTAATGTTTTCCCAAGT TTATTTTTTATTTTTAATTTTTTCCCCAAGTTTATTTTTCTATTTTTTTTTCATGGAAAAATGGGGTAACTTAGCAGTTTCAATATTGAA GACTGAAGTTTAAAAAAAATTTAAATTCAAGGTACTTTTAAAATTCAGTTAGAAAAGTAGGCTTTAAAAATTATTAGAGACAAGAGTACC AAAGCGGTGTGTGTATGTGTGTGTGTGTATGCATGCTTGTGGATTGGAAAAACTTTGGAGACTGATTACTTTTCATTATATATGTGTCAC AGTGAAACAGCTTTTATGTGTCATGTAAGATTACTGCTTGCCTCTCTAAGGAAGGTCGTGACTGTTTAAATAGACGGGCAAGGTGGAACC TTTTGAAAGATGAGCTTTTGAATATAAGTTGTCTGCTAGATCATGGTTTGTATTGAACTAACAAGGTTTGCAGATCTGCTGACTTATATA AAGCTTTTTGATTCCTACTAAGCTTTAAGATTTAAAAAATGTTCAATGTTGAAATTTCTGTGGGGCTCTATTTTTGCTTTGGCTTTCTGG TGAGAGAGTGAGGAAGCATTCTTTCCTTCACTAAGTTTGTCTTTCTTGTCTTCTGGATAGATTGATTTTAAGAGACTAAGGGAATTTACA AACTAAAGATTTTAGTCATCTGGTGGAAAAGGAGACTTTAAGATTGTTTAGGGCTGGGCGGGGTGACTCACATCTGTAATCCCAGCACTT TGGGAGGCCAAGGCAGGCAGAACACTTGAAGGAGTTCAAGACCAGCGTGGCCAACGTGGTGAAACCCTGTCTCTACTAAAAATACAAAAA TTGTTTAGCTCTGTTTTTCATAATAGAAATAGAAAAGGTAAAATTGCTTTTCTTCTGAAAAGAACAAGTATTGTTCATCCAAGAAGGGTT TTTGTGACTGAATCAGCAGTGCCTGCCCTAGTCATAGCTGTGCTTCAAAAACCTCAGCATGATTAGTGTTGGAGCAAAACAAGGAAGCAA AGCAAATACTGTTTTTGAAATTCTATCTGTTGCTTGAACTATTTTGTAATAATTAAACTTTGATGTTGAGAAATCACAACTTTATTGTAC ACTTCATTGCAACTTGAAATTCATGGTCTTAAAGTGAGATTTGAATTTCTATTGAGCGCCTTTAAAAAAGTAATACCAAACCATAAAGTT AAAATCTATGTATATTGAGTCATATCTAAAACCACGTATAAACATAAATTGTATTTCCTGTTTTAATTCCAGGGGAAGTACTGTTTGGGA AAGCTATTATTAGGTAAATGTTTTACAAATTACTGTTTCTCACTTTCAGTCATACCCTAATGATCCCAGCAAGATAATGTCCTGTCTTCT AAGATGTGCATCAAGCCTGGTACATACTGAAAACCCTATAAGGTCCTGGATAATTTTTGTTTGATTATTCATTGAAGAAACATTTATTTT CCAATTGTGTGAAGTTTTTGACTGTTAATAAAAGAATCTGTCAACCATCAAAGAGGTCTGCATTATGCTTGCATGTCAAAAACTTTAAAA ATCCTATAATCTTCTGTCATTTTCACTGAGTTTCCATGGGAAAGGAATAGTAAATAATGGGTAGTTGAAATATTACTCTTAAGACCAAGA CCTGTATCTCCAGTCATATCTGTAATAACATCATCTGATAACCTAAAAGCATAGTATTAGGGATATACGACAAAACCAAAGTGTTTTTGC TGTTGTCACATACCACTCAATACTTTTACACCAGGTTGTCCAGTGGACACCAGCTGGATGTCCTATAATTCAATTCTGACACTGTCTACC TGGAATTGGAGTCAGATCCCACAGGTGGAGGGCTCAGCCCACAAGACTGCCCCCACTCCAGATACCAATCGCAAGTCCCTATACTTCTGA CTGGCTATAAAGTGGGGTTCCCGTGACCCTTTCCTTGGTTTTGATTTATTTGCTAGAGCAGCTCCCAGAACACAGAGAAACACTCTACTT ATGTTTACCCATTTTTAATTTTATTACTTTATTAAAACTACATATTGGTTACAATACTAATTTATTGTAAAGGATATTTCATTTATTTAT TTTTTTATTTAGAGATGGAGTCTCACTGTGTCACCCAGGCTGGAGTGCGGTGGCACAGTCTCAACTCACTGCAACCTCCACCTCCTGAGT TCAAGCGATTCTCATGCCTCAGCCTCCCAAGTAGCTGGGATTACAAGTGTGCACCACCATGCCCAGCTAATTTTTGTATTTTTAGTAGAG ATGGGGTTTCACTCTGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGTCATCCACCCACCTCAGCCTCCCAAAGTGCTGAGATTACA GGTGTGAGCCATTGCCTCTGGCTTGTAAAGGATATTTCAAAGAATACAGATGAACAGCCAGATGGAAGAGATGCACAGGGCAAGGCATGT GGGAAGGGGTATGGAGCTTTCATGCTCTCTCCACGTCATCAGCTACCCAGAAGCTCATCTGGACCCCGACCCTTTGGGGTTTTACGGAGG CTTCATTATGTCAGCATTACCATTGGCAATTGGCGATTAACTCAACCTTCAGCCTCTCTCCCCTTTCTGGAGGTTGGGGGTTGAGGCTGG GAGTCCAAACCCTCCAATCTTGCCTTGGTCTTTCTGGTAAGCAGCCCCCCGTCCTGAAGCTACCTAGAGGCTCCCAGCCACCAATCATTT CATTGGCAAACCAAAGATACTTCAAGGGGTTTAGGAGCCAAGAGACCAAGCAAGGATTGAGACAATATATATATTTCTTATAAATAACAT GATCACAAATAGTATTTTATATATTTCTCATAATAGCTGGTTGTGGTTACTCACACCTATCATCCCAGCTACTAAGAAGCTAAGGCAGGA GGATCACAGGCCCAGGAGTTTGCAGCTGTAGTGAGCTATGATTGTGCTACTGCACTCCAGCCTGGGTGACAGTGTGAGACCCTGTCTCTT AAAGTTCTTGTAACATCTTAGAACATTAACCAACCACAGATTATTGCCTTAACTCTGAAAAATAAAGTAATCATACTTTTACAAGATGTA TTTTACATAAAGTTCTGGTGATATTTTACTCTGGTCATTGGAATATAGGAGCTTACCACCTGGTACCACTCTTCCTAAAGTGGTATACTA TTTGGTATAGTACTGGCATACTATTTGGAAAGGGATGTGAAGTTGGCATGACCTGTCTAGGGTGAAGTCATGCTGTCTGCTATTCATTGT GGGCTTTACAGTAATGAGAGTGCTTCTGTTGTCAAGATGCTTCTGGGACACGTTAAAAAAAATTTAAGATTTCTCAGTTTGTGAAAAGGA AGGAGCACGAATGCTTTCAAGTTCCTATGACATGCTAGTCATCTTTCAGTGTGTCCCATTGTTGCACCCAGTAGTCTCGATGCCCAGCGT CACGGTGATTCCAAGTTTGCCTCTCTGCCCACTATAATTTGTGCTCCATGAAGTCCCAGGACATGAGGTTCTTGTTCATTTGTGCGTCTG GGCCCATATCCAAATATTAAACAATGTGACTTAATGTATTTATCATATTGTAAATATGGGTATCCCCAAGGCTCAGAAGTTAACACAGCA TATCCACAGAGAGGTTTGACAGCATGGCTGTGGTGACTGGGAAGGCCTTATGCTTGCTCCTCCTTCTGCTGCTTGCCTTTGTGTGGGCAT GGAAAGAACATTGAATTAGGTACTGGAAGACCTGGGTCCTGGTCTTGGAGATTTTACCAGAGCACCTGTGGGATATTGGTCAAGATGCCT GGTTTTAGTCCTGCTCCTTTGCTGTGAAAGAGGATCTTAAGGTGCCAACTCTGGCATTTTATTTTTTACTTATTTATTTTTAAATTATAC TTTAAGTTCTAGGGTACATGTGTACAACATGCAGGTTTGTTACATGTATACATGTGCCATGTTGGTGTGCTGCACCTATTAACTCGTCAT TTACATTAGGTATATCTCCTAATGCTATCCCTCCCCCTTCTCCCCACCCCTCGACAGGCCCCGGTGTGTGATGTTCCCCTTCCTGTGTCC AAGTGTTCTCATTGTTCAATTCCCATCTATGAGTGAGAACATGCGGTGTTTGTTTTTTTGTCCTTGGAATAGTTTGCTGAGAAGGATGGT TTCCAGCTTCATCCATGTCCCTATAAAGGACATGAACTCTTCCTTTTTTATGGCTGCATAGTATTCCATGGTGTATATGTGCCACATCTT CTTAAACCAATCTATCATTGATGGACATTTGGGTTGGTTCCAAGTCTTTGCTATTGTGAACAGTGCCACAATAAATATACGTGTGCATGT GTCTTTATAGCAGCATGATTTATAATCCTTTGGGTATATACCCAGTAATGGGATGGCTGGGTCAAATGGTATTTCTAGTTCTAGATCCCT GAGGAATCGCCACACTGTCTTCCACAATGGTTGAACTAGTTTACAGTCCCACCACCAGTGTAAAAGTGTTCCTATTTCTCCACATCCTCT CCAGCACCTGTTGTTTCCTGACTTTTTAATGATTGACATTCTAACTGGTGTGAGATGGTATCTCATTGTGGTTTTGATTTGCATTTCTCT GATGGCCCATGATGATGAGCATTTTTTTCATGTGTCTGTTGGATGCATGGATGTCTTCTTTTGAGAAGTGTCTCTTCATATCCTTCACCT ACTTTTTGATGGGGTTTGTTTTTTTCTTGTAAGTTTGTTTGAGTTCCTTGTAGATTCTGGATATTAGCCCTTTGTCAGATGAGTAGATTG CAAAAATTTTCTCCCATTTTGTAGGTTGCCTGTTCACTCTGATGGTAGTTTCTTTTGCTGTGCAGAAGCTCTTGAGTTTAATGAGATCCC ATTTGTCAATTTTGGCTTCTGTTGCCATTGCTTTTGGTGTTTTAGACATGAAGTCCTTGCCCATGCCTGTGTCCTGAATGGTACTGCATA GGTTTTCTTCTAGGGTTTTTATGGTTTTAGGTCTAACATTTAAGTCTTTAATCCATCTTGAATTAATTTTTGTATAAGGTGTAAGGAAGG GATCCAGTTTCAGCTTTCTACATGTGGCTAGCCAGTTTTCCCAGCACCATTTATTAAATAGGGAATCCTTTCCCCATTTCTTGTTTTTGT CAGGTTTCTCAAAGATCAGATAGTTGTAGATGTGTGGTATTATTTCTGAGGGCTCTGTTCTGTTCCATTGGTCTATATCTCTGTTTTGGT ACTAGTACCATGCTGTTTTGGTTACTGCAGCCTTGTAGTATAGTTTGAAATCAGGTAGCGTGATGCCTCCAGCTTTGTTCTTTTGGCTTA GGATCGTTTTGGCAGTGCAGGCTCTTTTTTGGTTCCACATGAACTTTAAAGTAGTTTTTTCCAATTCTATGAAGAAAGTCATGGGTAGCT TGATGGGGATGGCATTGAATCTATAAATTACCTTGGGCAGTATAGCCATTTTCACGATATTGATTCTTCCTATCCATGAGCATGGAATGT TCTTCCATTTGTTTGTGTCCTCTTTTATTTCCTTGAGCAGTGGTTTGTAGTTCTCCTTGAAGAGGTCCTTCACATCCCTTGTAAGTTGGA TTCCTAGGTATTTTATTCTCTTTGAGGCAGTTGTGAATGGGAGTTCACTCATGATTTGGCTCTCTGTTTGTCTGTTGTTGGTGTATAAGA ATGCTTGTGATTTTTGCACATTGATTTTGTATCCTGAGATTTTGCTGAAGTTGCTTATCAAATTAAGGAGATTTTGGGCTGAGATGATGG GGTTTTCTAAATATAAAATCATGTCATCTGCAAACAGGGACAATTTGACTTCCTCTTTTCCTTATTGAATACCCTTTATTTCTTTCTCCT GCCTGATGGCCCTGGCCAGAACTTCCAACACTATGTTGAATAGGAGTGGTGAGAGAGGGCATCCCTGTCTTGTGCCAGTTTTCAAAGGGA ATGCTTCCAGTTTTTGCCCATTCAGTCTGATATTGGCTGTGGGTTTGTCATAGATAGCTCTTATTATTTTGAGATATGTCCCATCAATAC CTAATTCATTGAGAGTTTTTAGCATGAAGGGCTGTTGAATTTTGTCCAAGGCCTTTTCTGCATCTGTTGAGATAATCATGTGGTTTTTGT CTTTGGTTCTGTTTATATGCTGGATTACTTTTATTGATTTGTGTATGTTGAACCAGCCTTGCATCCCAGGGATGAAGCCCACTTGATCAT GGTGGATAAGCTTTTTGATATGCTGCTGGATTCAGTTTGCCAGTATTTTATTGAGGATTTTTGCATTGATTTTCATCAGGGATATTGGTC TAAAGTTCTCTTTTTTTGTTATGTCTCTGCCAGGCTTTGGTATCAGGATGATGCTGGCTTCATAAAATGAGTTAGGGAGGATTCCCTCTT TTTCTATTGATTGGAATAGTTTCAGAAGGAATGGTACCAGCTCTTCCTTGTACCTCTGGTAGAATTCGGCTGTGAATCCATCTTGTCCTG GACTTTTTTTGGTTGGTAGGCTATTAATTATTGCCTCAATTTCAGAGCCTGTTATTGGTCTATTCAGGGATTAAACTTCTTCCTGGTTTA GTTTTGAGAGGGTGTATGTGTCCAGGAATTTATCTATTTCTTCTAGATTTTCTAGTTTATTTGCATAGAGGTGTTTATAGTATTCTCTGT GTACTCTGTATTTCTGTGGGATTGGTGGTGATATCCACTTTATCATTTTTTATTGCATTTATTTGATTCTTCTCTCTTTTCTTGTTTATT AGTCTTGCTAGCGGTCTATCAATTGTGTTTATCTTTTCAAAAAACCAGCTCCTGGATTCATTCATTTTTTGAAGGTTTTTTTGTGTCTCT GTCTCCTTCAGTTCTGCTCTGATCTTAGTTATTTCTTGTCTTCTGCTAGCTGTTGAATGTGTTTGCTCTTGCTTCTCTAATATTTTTAAT TGTGATGTTAGAGTGTCAATTTTAGATCTTTCCTGCTTTCTCTTGTGGGCACTTAGTGCTGTAAATTTCCCTCTACACACTGCTTTAAAT GTGTCCCAGAGATTCTGGTATGTTGTGTCTTTGTTCTCGTTGGTTTCAAAGAACATCTTTATTTCTGCCTTCATTTTGTTATGTACCCAG TAGTCATTCAGGAGCAGGTTGTTCAGTTTCCATGTAGCTGAGTGGTTTTGAGTGAGTTTCTTAATCCTGAGTTCTAGTTTGATTGCACTG TGGTCTGAGACAGTATGTTATAATTTCTGTTCTTTTACATTTGCTGAGGAGTGCTTTACTTCCAACTATGTGGTCAATTTTGGAATAGGT GCGATGTGGTGCTGAGAAGAATGTATATTCTGTTGATTTGGGGTGGAGAGTTCTGTAGATGTCTATTAGGTCTGCTTGGTGCAGAGCTGA ATTCAATTCCTGGATATCCTTGTTAACTTTCTGTCTCGTTGATCTGTCTAATATTGACAGTGGGGTGTTAGAGTCTCCCATTGTTATTGT GTGGGAGTCTAAATCTCTTTGTAGGTCTCTAAGGACTTGGTTTATGAATCTGGGTGCTCCTGTATTGGGTGCATATATATTTAAGATAGT TAGCTCTTCTTGTTGAATTGATCCCTTTACTATCATGTAATGGCCTTCTTTGTCTCTTTTGATCTTTGTTGGTTTAAAGTCTGTTTTATC AGAGACTAGGATTGCAACCCCGGCCTTTTTTTTTGTTTTCCGTTTGCTTGGTAGATCTTCCTCCATCCTTTTATTTTGAGCCTATGTGTG TGTGTCTCTGTACGTGAGATGGGTTTCCTGAATACAGCACCCTGATGGGTCTTGACTCTTTATCCAGTGTGCCAGTCTGTGTCTTTTAAT TGGAGCATTTAGCCCATTTACATTTAAGGTTAATATTGTTATGTGTGAATTTGATCCTGTCACTAGGATGTTCACTGGTTATTTTGCTCG TTAGTTGATGCAGTTTCTTCCTAGCCTCAATGGTCTTTACAATTTGGCATGTTTTTGCAGTGGCTGATACTGGTTGTTCCATTCCATGTT TAGTGCTTCCTTCAGGAGCTCTTGTAAGGCAGGCCTGGTGGTGACAAAATCTCTCAGCATTTGCTTGTTTGTAAAGGATTTTATTTCTCC TTCACTTATGAAGCTTAGTTTGGCTGGATATGAAATTCTGGGTTGAAAATTCTTTTCTTCAAGAACGTTGAATATTGACCCCCACTCTCT TCTGGCTTGTAGAGTTTCTGCTGAGAGATCAGCTGTTAGTCTGATGGGCTTCCCTTTGTGGGTAACCCGACCTTTCTCTCTGGCTGCCCT TAACATTTTTTCCTTCATTTCAACTTTGGTGAATCTGACAATTATGTGTCTTGGAGTTGCTCTTCTCGAGGAGTATCTTTGTGGCGTTCT CTGTATTTCCTGAATTTGAATGTTGTCCTCCCTTGCTAGATTGGGGAAGTTCTCCTGGATAATATCCTGCAGAGTGTTTTCCAGCTTGGT TCCATTCTCCCCGTCACTTTCAGGTACACCAATCAGACGTAGATTTGGTCTTTTCACATAGTCCCATATTTCTTGGAAGCTTTGTTCGTT TCTTTTTACTCTTTTTTCTCTTAACTTCTCTTCTCACTTCATTTCATTCATCTGATCTTCAATCACTGATAACCTTTCTTCCAGTTGATC GAATTGGCTACTGAAGCTTGTGCATTCGTCACGTAGTTCTCATGCCATGGTTTTCAGCTCCATCAGGTCATTTAAGGACTTCTCTATGCT GGTTATTCTAGTTAGCCATTTGTCTAATCTTTTTTCAAGGTTTTTAGGTTCTTTGTGATGGGTTCGAACTTCCTCTTTTAGCTTGGAGAA GTTTGATCATCTGAAGCCTTCTTCTCTCAACTCGTCAAAGTCATTCTCCGTCCAGCTTTGTTCTGTTGCTGGCAAGGAGCTATGTTCCTT TGGAGGGGGAGAGGCGCTCTGATTTTTAGAATTTTCAGCTTTTCTGCTCTGTTTTTTCCCCATCTTTGTGGTTTTATCTACCTTTGGTCT TTGGTGATGGTGATGTGCAGATGGGGTTTTGGTGTGGATGTCCTTTCTGTTTGTTAGTTTTCCTTCTAACAGTCAGGACCGCCAGCTGCA GGTCTGTTGGAGTTTGCTGGACGTCCACGCCAGACCCTGTTTGCCTGGGTATCACAGTGGAGGCTGTAGAACAGCGAATATTGCTGAACA GCAAATGTTGCTGCCTGATCATTCCTCTGGAAGCTTCATCTCAGAGGGGTACCCGGCCATGTGGGGTGTCAGTCTGCCCCTACTTGGGGG TGCCTCCCAGTTAGGCTACTCGGGGGTCAGGGACTCACTTGAGGAGGCAGTCTCTCCGTTCTCAGATCTCAAACTCTGTGCTGGGAGAAC CACTGGTCTCTTCAAAGCTGTCAGACAGGGACATTGAAGTCTGCAGAGATTTCTGCTGCCTTTTGTTCGGCTATGCCATGCCCCCAGAGG TGGAGTCTACAGAGGCAGGCAGGCAGGCCTCCTTGAGCTGCAGTGGGCTCCACCTAGTTCGAGCTTCCCGGCTGCTTTATTTACCTACTG AAGCCTCAGCAATGGTGGGCTCCCCTCCCCTAGCCTCACTGCCACCTTGCAGTTCGATCTCAGACTGCTGTGCTAGCAATGAGCAAGGCT CCATGGGCGTGGGACCCTCCGAGCTAGGCACAGGATATAATCTCCTGGTGTGCCGTTTGCTAAGACCATTGGAAAAACGCAGTATTAGGG TGGGAGTGACCCAATTTTCCAGGTGCCGTCTGTCACAGCTTCCCTTGGCTAGGAAAGGGAATTCCCTGACCCCTTGCCTTCCCGGGTGAG GCCATGCCTTGCCCTGCTTCAGCTCATGCTCAGTGGGCTGCACCCACCGTCCTACACCCACTGTCCAACAAGCCCCAGTGAGATGAACCT GGTACCTCAGTTGGAAGTGCAGAAATCACCTGTCTTCTGCGTCGCTCACGCTGGGAGCTGTAGACTGGAGCTGTTCCTATTCGGCCATCT TGGAACCCAACCCAAGTCTGGCATTTTTTGGTTTTCTCTGTGTATTGACTATGATTATAGAGGATAAATGGATATTGATATTATTAAATC GTCATTTACAGAAGGCACACAACTTATATCCTTTAAACAAAGTTCTCCAACCAGTAGGGTATACTTGCTGGTAGTGCTTACAGCTGCCAC CATTCTTCACTGGGGCTCAGAGTGGATGCCTGGAGGAAAAAAACAAATGAATCTTTTAGCTCCTAGTTACTGTTAGCATTTTTACCAGAA AACAATTTAAAAAATGACACAAGTAAGTCTTCACCTATCAAGGCTGAGTGTGGTGGCCTATACTTGTAATCTCTGTGCTTTGGGAGGCCA ACGCAGGAGGATCTCTTGAGTCCAGGAGTTTGAGACCAGCCTGGGCAACAAAGCAAGACCCCATCTCTACAGAAAGTTAAAATTTAGCTG GGCATGCTGGCACATCCCTATAGTCCCAGCTACTTGAGAGGCTGAGTTGGGAGGATCCCTTGAGGTCATGAGTTGGAGTCTACAGTGAGC TGTGATTACAGTGTGAGTCTACACTGCACTCCAGTCTGGGTGAAAGAGATCCTGTCTCTCAAAAAACAAGTGATTCTCCTGGGAAGAGAT TTGTTTAAAAAGTCTGCACCTCTATTGATGATAACTTTGAATGTAAATGGATTAAATTCTCCCACTTAAAAGATATAGATTGACTGAATG GATTAAAAACCACCATCATGACTCGACTGTATGCTGCCTACAAGAAACCTCACCTGTAAAGACAGGCCAAAAGTGAAGGTATGGAGAAAG ATATTGCATACAAATGGAAGCCAAAAAAGAGCAGAAATAACTATACTTACATGAGATAAAATAGACTTTAAGTCAAAAACTGTAAAAAGA AAAGTCATTATGTAATGAAACAAGGATCAATTCATGCAAGATATAATCATATTTTTTTATTAAGAAAATTTTTTTGTAGAGATGGGGTTA TGCTATGTTGCCTGGCTAGTCTCAAACTCTGGGTCTCAAAGCAGTCCTCCTGCTTTGGCCTCCTAAGGTGCTGGGATTATAGGCATGAGC CACTGTGCCAGGCCTGAGGATATTATCATTATAAATATATATGTACCCCACACTGGATGACCCAGATATAAAGCAAATATTATTAGATTT AAAGGGAGAAATAGACTCTAATACAATAGTAGTTGAGGACTTCACTCTACTCTCAGCATTGGACAGATTTTCTAGACATAAAACCAATAA ATATTGGATTTAAATTGCACTTTACACCAAATGGACCTGACATTTACAGAACATTCTAATAGGTGCAGAACACTCTAATAGCTGCAGAAC ACACGTTCTTTTCATCAGCACATGGAACATTCACCAGACTAGTTCTGGAACCCACTTCCTGCCTTAGTGTTCTTTCCACCACAGTGCATG ATAATTCCGACAGAACGCCTTTTATTTGTACCTTATTAGTTGTAGGGGGAAAGCTTTTTCATGTACAAAAATGCTGTAATTTTCTGATTT >In-frame_ENST00000429426_ENST00000538183_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(amino acids)=208AA_start in transcript=98_stop in transcript=724 MCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRGDVTAQIALQPALKFNGGGHINHSIFWTN LSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYK -------------------------------------------------------------- >In-frame_ENST00000429426_ENST00000367055_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(transcript)=979nt_BP=282nt ATATTTCAGCCGCCGCCGCCGGGAGCTGCGGGCACAGTCCGGGGACGCGGCGAGCAGCCTCGGCGGCCGCACCTCCGCAAAGCGCCGCGG CCGCTACGATGTGTGCCGTGCAGGTGAAGCTGGAGCTGGGGCACCGCGCCCAGGTGAGGAAAAAACCCACCGTGGAGGGCTTCACCCACG ACTGGATGGTGTTCGTACGCGGTCCGGAGCACAGTAACATACAGCACTTTGTGGAGAAAGTCGTCTTCCACTTGCACGAAAGCTTTCCTA GGCCAAAAAGAGGAGATGTTACAGCCCAGATAGCTCTTCAGCCTGCACTGAAGTTCAATGGTGGTGGTCATATCAATCATAGCATTTTCT GGACAAACCTCAGCCCTAACGGTGGTGGAGAACCCAAAGGGGAGTTGCTGGAAGCCATCAAACGTGACTTTGGTTCCTTTGACAAGTTTA AGGAGAAGCTGACGGCTGCATCTGTTGGTGTCCAAGGCTCAGGTTGGGGTTGGCTTGGTTTCAATAAGGAACGGGGACACTTACAAATTG CTGCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGCTTACTACCTTC AGTATAAAAATGTCAGGCCTGATTATCTAAAAGCTATTTGGAATGTAATCAACTGGGAGAATGTAACTGAAAGATACATGGCTTGCAAAA AGTAAACCACGATCGTTATGCTGATCATACCCTAATGATCCCAGCAAGATAATGTCCTGTCTTCTAAGATGTGCATCAAGCCTGGTACAT ACTGAAAACCCTATAAGGTCCTGGATAATTTTTGTTTGATTATTCATTGAAGAAACATTTATTTTCCAATTGTGTGAAGTTTTTGACTGT >In-frame_ENST00000429426_ENST00000367055_TCGA-CD-A48C-01A_MLLT3_chr9_20620653_-_SOD2_chr6_160109274_length(amino acids)=208AA_start in transcript=98_stop in transcript=724 MCAVQVKLELGHRAQVRKKPTVEGFTHDWMVFVRGPEHSNIQHFVEKVVFHLHESFPRPKRGDVTAQIALQPALKFNGGGHINHSIFWTN LSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYK -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for MLLT3-SOD2 |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for MLLT3-SOD2 |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for MLLT3-SOD2 |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Hgene | MLLT3 | C0005586 | Bipolar Disorder | 1 | PSYGENET |
Tgene | SOD2 | C0033578 | Prostatic Neoplasms | 8 | CTD_human |
Tgene | SOD2 | C0376358 | Malignant neoplasm of prostate | 8 | CTD_human |
Tgene | SOD2 | C0235874 | Disease Exacerbation | 7 | CTD_human |
Tgene | SOD2 | C0006826 | Malignant Neoplasms | 6 | CTD_human |
Tgene | SOD2 | C0027626 | Neoplasm Invasiveness | 6 | CTD_human |
Tgene | SOD2 | C0027651 | Neoplasms | 6 | CTD_human |
Tgene | SOD2 | C0035126 | Reperfusion Injury | 6 | CTD_human |
Tgene | SOD2 | C0086692 | Benign Neoplasm | 6 | CTD_human |
Tgene | SOD2 | C0007621 | Neoplastic Cell Transformation | 5 | CTD_human |
Tgene | SOD2 | C0018801 | Heart failure | 5 | CTD_human |
Tgene | SOD2 | C0018802 | Congestive heart failure | 5 | CTD_human |
Tgene | SOD2 | C0023212 | Left-Sided Heart Failure | 5 | CTD_human |
Tgene | SOD2 | C0235527 | Heart Failure, Right-Sided | 5 | CTD_human |
Tgene | SOD2 | C1959583 | Myocardial Failure | 5 | CTD_human |
Tgene | SOD2 | C1961112 | Heart Decompensation | 5 | CTD_human |
Tgene | SOD2 | C0006142 | Malignant neoplasm of breast | 4 | CTD_human |
Tgene | SOD2 | C0007114 | Malignant neoplasm of skin | 4 | CTD_human |
Tgene | SOD2 | C0024623 | Malignant neoplasm of stomach | 4 | CTD_human |
Tgene | SOD2 | C0025500 | Mesothelioma | 4 | CTD_human |
Tgene | SOD2 | C0027627 | Neoplasm Metastasis | 4 | CTD_human |
Tgene | SOD2 | C0036341 | Schizophrenia | 4 | PSYGENET |
Tgene | SOD2 | C0037286 | Skin Neoplasms | 4 | CTD_human |
Tgene | SOD2 | C0038356 | Stomach Neoplasms | 4 | CTD_human |
Tgene | SOD2 | C0678222 | Breast Carcinoma | 4 | CTD_human |
Tgene | SOD2 | C1257931 | Mammary Neoplasms, Human | 4 | CTD_human |
Tgene | SOD2 | C1458155 | Mammary Neoplasms | 4 | CTD_human |
Tgene | SOD2 | C1708349 | Hereditary Diffuse Gastric Cancer | 4 | CTD_human |
Tgene | SOD2 | C2239176 | Liver carcinoma | 4 | CTD_human |
Tgene | SOD2 | C4704874 | Mammary Carcinoma, Human | 4 | CTD_human |
Tgene | SOD2 | C0003873 | Rheumatoid Arthritis | 3 | CTD_human |
Tgene | SOD2 | C0007786 | Brain Ischemia | 3 | CTD_human |
Tgene | SOD2 | C0020538 | Hypertensive disease | 3 | CTD_human |
Tgene | SOD2 | C0024232 | Lymphatic Metastasis | 3 | CTD_human |
Tgene | SOD2 | C0028754 | Obesity | 3 | CTD_human |
Tgene | SOD2 | C0029408 | Degenerative polyarthritis | 3 | CTD_human |
Tgene | SOD2 | C0030567 | Parkinson Disease | 3 | CTD_human |
Tgene | SOD2 | C0086743 | Osteoarthrosis Deformans | 3 | CTD_human |
Tgene | SOD2 | C0270715 | Degenerative Diseases, Central Nervous System | 3 | CTD_human |
Tgene | SOD2 | C0524851 | Neurodegenerative Disorders | 3 | CTD_human |
Tgene | SOD2 | C0751733 | Degenerative Diseases, Spinal Cord | 3 | CTD_human |
Tgene | SOD2 | C0917798 | Cerebral Ischemia | 3 | CTD_human |
Tgene | SOD2 | C0002152 | Alloxan Diabetes | 2 | CTD_human |
Tgene | SOD2 | C0002896 | Sideroblastic anemia | 2 | CTD_human |
Tgene | SOD2 | C0003129 | Anoxemia | 2 | CTD_human |
Tgene | SOD2 | C0003130 | Anoxia | 2 | CTD_human |
Tgene | SOD2 | C0004153 | Atherosclerosis | 2 | CTD_human |
Tgene | SOD2 | C0005586 | Bipolar Disorder | 2 | PSYGENET |
Tgene | SOD2 | C0005684 | Malignant neoplasm of urinary bladder | 2 | CTD_human |
Tgene | SOD2 | C0005695 | Bladder Neoplasm | 2 | CTD_human |
Tgene | SOD2 | C0007097 | Carcinoma | 2 | CTD_human |
Tgene | SOD2 | C0007131 | Non-Small Cell Lung Carcinoma | 2 | CTD_human |
Tgene | SOD2 | C0007137 | Squamous cell carcinoma | 2 | CTD_human |
Tgene | SOD2 | C0007193 | Cardiomyopathy, Dilated | 2 | CTD_human |
Tgene | SOD2 | C0009402 | Colorectal Carcinoma | 2 | CTD_human |
Tgene | SOD2 | C0009404 | Colorectal Neoplasms | 2 | CTD_human |
Tgene | SOD2 | C0011853 | Diabetes Mellitus, Experimental | 2 | CTD_human |
Tgene | SOD2 | C0014859 | Esophageal Neoplasms | 2 | CTD_human |
Tgene | SOD2 | C0022116 | Ischemia | 2 | CTD_human |
Tgene | SOD2 | C0022658 | Kidney Diseases | 2 | CTD_human |
Tgene | SOD2 | C0026640 | Mouth Neoplasms | 2 | CTD_human |
Tgene | SOD2 | C0027540 | Necrosis | 2 | CTD_human |
Tgene | SOD2 | C0032927 | Precancerous Conditions | 2 | CTD_human |
Tgene | SOD2 | C0034535 | Radiation Syndrome | 2 | CTD_human |
Tgene | SOD2 | C0038433 | Streptozotocin Diabetes | 2 | CTD_human |
Tgene | SOD2 | C0042164 | Uveitis | 2 | CTD_human |
Tgene | SOD2 | C0085207 | Gestational Diabetes | 2 | CTD_human |
Tgene | SOD2 | C0153381 | Malignant neoplasm of mouth | 2 | CTD_human |
Tgene | SOD2 | C0162674 | Chronic progressive external ophthalmoplegia | 2 | CTD_human |
Tgene | SOD2 | C0205696 | Anaplastic carcinoma | 2 | CTD_human |
Tgene | SOD2 | C0205697 | Carcinoma, Spindle-Cell | 2 | CTD_human |
Tgene | SOD2 | C0205698 | Undifferentiated carcinoma | 2 | CTD_human |
Tgene | SOD2 | C0205699 | Carcinomatosis | 2 | CTD_human |
Tgene | SOD2 | C0242184 | Hypoxia | 2 | CTD_human |
Tgene | SOD2 | C0279626 | Squamous cell carcinoma of esophagus | 2 | CTD_human |
Tgene | SOD2 | C0282313 | Condition, Preneoplastic | 2 | CTD_human |
Tgene | SOD2 | C0546837 | Malignant neoplasm of esophagus | 2 | CTD_human |
Tgene | SOD2 | C0700292 | Hypoxemia | 2 | CTD_human |
Tgene | SOD2 | C0919267 | ovarian neoplasm | 2 | CTD_human |
Tgene | SOD2 | C1140680 | Malignant neoplasm of ovary | 2 | CTD_human |
Tgene | SOD2 | C1449563 | Cardiomyopathy, Familial Idiopathic | 2 | CTD_human |
Tgene | SOD2 | C1510432 | Radiation Sickness | 2 | CTD_human |
Tgene | SOD2 | C1563937 | Atherogenesis | 2 | CTD_human |
Tgene | SOD2 | C0001418 | Adenocarcinoma | 1 | CTD_human |
Tgene | SOD2 | C0001787 | Osteoporosis, Age-Related | 1 | CTD_human |
Tgene | SOD2 | C0001925 | Albuminuria | 1 | CTD_human |
Tgene | SOD2 | C0001969 | Alcoholic Intoxication | 1 | PSYGENET |
Tgene | SOD2 | C0002390 | Extrinsic allergic alveolitis | 1 | CTD_human |
Tgene | SOD2 | C0002395 | Alzheimer's Disease | 1 | CTD_human |
Tgene | SOD2 | C0002736 | Amyotrophic Lateral Sclerosis | 1 | CTD_human |
Tgene | SOD2 | C0002871 | Anemia | 1 | CTD_human |
Tgene | SOD2 | C0003493 | Aortic Diseases | 1 | CTD_human |
Tgene | SOD2 | C0004045 | Asphyxia Neonatorum | 1 | CTD_human |
Tgene | SOD2 | C0004364 | Autoimmune Diseases | 1 | CTD_human |
Tgene | SOD2 | C0006118 | Brain Neoplasms | 1 | CTD_human |
Tgene | SOD2 | C0007102 | Malignant tumor of colon | 1 | CTD_human |
Tgene | SOD2 | C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C0007682 | CNS disorder | 1 | CTD_human |
Tgene | SOD2 | C0007787 | Transient Ischemic Attack | 1 | CTD_human |
Tgene | SOD2 | C0009375 | Colonic Neoplasms | 1 | CTD_human |
Tgene | SOD2 | C0011265 | Presenile dementia | 1 | CTD_human |
Tgene | SOD2 | C0011570 | Mental Depression | 1 | PSYGENET |
Tgene | SOD2 | C0011574 | Involutional Depression | 1 | CTD_human |
Tgene | SOD2 | C0011581 | Depressive disorder | 1 | PSYGENET |
Tgene | SOD2 | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human |
Tgene | SOD2 | C0011881 | Diabetic Nephropathy | 1 | CTD_human |
Tgene | SOD2 | C0014866 | Esophageal Stenosis | 1 | CTD_human |
Tgene | SOD2 | C0014868 | Esophagitis | 1 | CTD_human |
Tgene | SOD2 | C0015695 | Fatty Liver | 1 | CTD_human |
Tgene | SOD2 | C0015967 | Fever | 1 | CTD_human |
Tgene | SOD2 | C0016059 | Fibrosis | 1 | CTD_human |
Tgene | SOD2 | C0017667 | Nodular glomerulosclerosis | 1 | CTD_human |
Tgene | SOD2 | C0018200 | Granuloma, Respiratory Tract | 1 | CTD_human |
Tgene | SOD2 | C0018800 | Cardiomegaly | 1 | CTD_human |
Tgene | SOD2 | C0019193 | Hepatitis, Toxic | 1 | CTD_human |
Tgene | SOD2 | C0020542 | Pulmonary Hypertension | 1 | CTD_human |
Tgene | SOD2 | C0020550 | Hyperthyroidism | 1 | CTD_human |
Tgene | SOD2 | C0020615 | Hypoglycemia | 1 | CTD_human |
Tgene | SOD2 | C0021364 | Male infertility | 1 | CTD_human |
Tgene | SOD2 | C0021367 | Mammary Ductal Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C0021655 | Insulin Resistance | 1 | CTD_human |
Tgene | SOD2 | C0022333 | Jacksonian Seizure | 1 | CTD_human |
Tgene | SOD2 | C0022665 | Kidney Neoplasm | 1 | CTD_human |
Tgene | SOD2 | C0022672 | Acute Kidney Tubular Necrosis | 1 | CTD_human |
Tgene | SOD2 | C0023891 | Liver Cirrhosis, Alcoholic | 1 | CTD_human |
Tgene | SOD2 | C0024115 | Lung diseases | 1 | CTD_human |
Tgene | SOD2 | C0024668 | Mammary Neoplasms, Experimental | 1 | CTD_human |
Tgene | SOD2 | C0024796 | Marfan Syndrome | 1 | CTD_human |
Tgene | SOD2 | C0025312 | Meningomyelocele | 1 | CTD_human |
Tgene | SOD2 | C0026764 | Multiple Myeloma | 1 | CTD_human |
Tgene | SOD2 | C0027051 | Myocardial Infarction | 1 | CTD_human |
Tgene | SOD2 | C0027726 | Nephrotic Syndrome | 1 | CTD_human |
Tgene | SOD2 | C0027746 | Nerve Degeneration | 1 | CTD_human |
Tgene | SOD2 | C0029456 | Osteoporosis | 1 | CTD_human |
Tgene | SOD2 | C0029459 | Osteoporosis, Senile | 1 | CTD_human |
Tgene | SOD2 | C0030246 | Pustulosis of Palms and Soles | 1 | CTD_human |
Tgene | SOD2 | C0030297 | Pancreatic Neoplasm | 1 | CTD_human |
Tgene | SOD2 | C0030354 | Papilloma | 1 | CTD_human |
Tgene | SOD2 | C0032580 | Adenomatous Polyposis Coli | 1 | CTD_human |
Tgene | SOD2 | C0033141 | Cardiomyopathies, Primary | 1 | CTD_human |
Tgene | SOD2 | C0033860 | Psoriasis | 1 | CTD_human |
Tgene | SOD2 | C0033937 | Psychoses, Drug | 1 | CTD_human |
Tgene | SOD2 | C0033941 | Psychoses, Substance-Induced | 1 | CTD_human |
Tgene | SOD2 | C0035222 | Respiratory Distress Syndrome, Adult | 1 | CTD_human |
Tgene | SOD2 | C0036202 | Sarcoidosis | 1 | CTD_human |
Tgene | SOD2 | C0036529 | Myocardial Diseases, Secondary | 1 | CTD_human |
Tgene | SOD2 | C0036572 | Seizures | 1 | CTD_human |
Tgene | SOD2 | C0036980 | Shock, Cardiogenic | 1 | CTD_human |
Tgene | SOD2 | C0037268 | Skin Abnormalities | 1 | CTD_human |
Tgene | SOD2 | C0037274 | Dermatologic disorders | 1 | CTD_human |
Tgene | SOD2 | C0040411 | Tongue Neoplasms | 1 | CTD_human |
Tgene | SOD2 | C0041408 | Turner Syndrome | 1 | CTD_human |
Tgene | SOD2 | C0042373 | Vascular Diseases | 1 | CTD_human |
Tgene | SOD2 | C0079744 | Diffuse Large B-Cell Lymphoma | 1 | CTD_human |
Tgene | SOD2 | C0086664 | Myelocele | 1 | CTD_human |
Tgene | SOD2 | C0149958 | Complex partial seizures | 1 | CTD_human |
Tgene | SOD2 | C0151526 | Premature Birth | 1 | CTD_human |
Tgene | SOD2 | C0151744 | Myocardial Ischemia | 1 | CTD_human |
Tgene | SOD2 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
Tgene | SOD2 | C0153349 | Malignant neoplasm of tongue | 1 | CTD_human |
Tgene | SOD2 | C0153633 | Malignant neoplasm of brain | 1 | CTD_human |
Tgene | SOD2 | C0162309 | Adrenoleukodystrophy | 1 | CTD_human |
Tgene | SOD2 | C0162671 | MELAS Syndrome | 1 | CTD_human |
Tgene | SOD2 | C0162871 | Aortic Aneurysm, Abdominal | 1 | CTD_human |
Tgene | SOD2 | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
Tgene | SOD2 | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
Tgene | SOD2 | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
Tgene | SOD2 | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
Tgene | SOD2 | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
Tgene | SOD2 | C0205874 | Papilloma, Squamous Cell | 1 | CTD_human |
Tgene | SOD2 | C0205875 | Papillomatosis | 1 | CTD_human |
Tgene | SOD2 | C0206061 | Pneumonia, Interstitial | 1 | CTD_human |
Tgene | SOD2 | C0206062 | Lung Diseases, Interstitial | 1 | CTD_human |
Tgene | SOD2 | C0206160 | Reticulocytosis | 1 | CTD_human |
Tgene | SOD2 | C0234533 | Generalized seizures | 1 | CTD_human |
Tgene | SOD2 | C0234535 | Clonic Seizures | 1 | CTD_human |
Tgene | SOD2 | C0235974 | Pancreatic carcinoma | 1 | CTD_human |
Tgene | SOD2 | C0238281 | Middle Cerebral Artery Syndrome | 1 | CTD_human |
Tgene | SOD2 | C0238461 | Anaplastic thyroid carcinoma | 1 | CTD_human |
Tgene | SOD2 | C0242526 | Gonadal Dysgenesis, 45,X | 1 | CTD_human |
Tgene | SOD2 | C0242698 | Ventricular Dysfunction, Left | 1 | CTD_human |
Tgene | SOD2 | C0242992 | Multiple Chemical Sensitivity | 1 | CTD_human |
Tgene | SOD2 | C0268255 | Farber Lipogranulomatosis | 1 | CTD_human |
Tgene | SOD2 | C0268583 | Methylmalonic acidemia | 1 | CTD_human |
Tgene | SOD2 | C0270824 | Visual seizure | 1 | CTD_human |
Tgene | SOD2 | C0270844 | Tonic Seizures | 1 | CTD_human |
Tgene | SOD2 | C0270846 | Epileptic drop attack | 1 | CTD_human |
Tgene | SOD2 | C0271708 | Fasting Hypoglycemia | 1 | CTD_human |
Tgene | SOD2 | C0271710 | Reactive hypoglycemia | 1 | CTD_human |
Tgene | SOD2 | C0274861 | Arsenic Poisoning, Inorganic | 1 | CTD_human |
Tgene | SOD2 | C0274862 | Nervous System, Organic Arsenic Poisoning | 1 | CTD_human |
Tgene | SOD2 | C0276496 | Familial Alzheimer Disease (FAD) | 1 | CTD_human |
Tgene | SOD2 | C0279702 | Conventional (Clear Cell) Renal Cell Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C0311375 | Arsenic Poisoning | 1 | CTD_human |
Tgene | SOD2 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
Tgene | SOD2 | C0346647 | Malignant neoplasm of pancreas | 1 | CTD_human |
Tgene | SOD2 | C0376618 | Endotoxemia | 1 | CTD_human |
Tgene | SOD2 | C0393554 | Amyotrophic Lateral Sclerosis With Dementia | 1 | CTD_human |
Tgene | SOD2 | C0422850 | Seizures, Somatosensory | 1 | CTD_human |
Tgene | SOD2 | C0422852 | Seizures, Auditory | 1 | CTD_human |
Tgene | SOD2 | C0422853 | Olfactory seizure | 1 | CTD_human |
Tgene | SOD2 | C0422854 | Gustatory seizure | 1 | CTD_human |
Tgene | SOD2 | C0422855 | Vertiginous seizure | 1 | CTD_human |
Tgene | SOD2 | C0472381 | Posterior Circulation Transient Ischemic Attack | 1 | CTD_human |
Tgene | SOD2 | C0494463 | Alzheimer Disease, Late Onset | 1 | CTD_human |
Tgene | SOD2 | C0494475 | Tonic - clonic seizures | 1 | CTD_human |
Tgene | SOD2 | C0496899 | Benign neoplasm of brain, unspecified | 1 | CTD_human |
Tgene | SOD2 | C0520459 | Necrotizing Enterocolitis | 1 | CTD_human |
Tgene | SOD2 | C0543859 | Amyotrophic Lateral Sclerosis, Guam Form | 1 | CTD_human |
Tgene | SOD2 | C0546126 | Acute Confusional Senile Dementia | 1 | CTD_human |
Tgene | SOD2 | C0740376 | Middle Cerebral Artery Thrombosis | 1 | CTD_human |
Tgene | SOD2 | C0740391 | Middle Cerebral Artery Occlusion | 1 | CTD_human |
Tgene | SOD2 | C0740392 | Infarction, Middle Cerebral Artery | 1 | CTD_human |
Tgene | SOD2 | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human |
Tgene | SOD2 | C0750900 | Alzheimer's Disease, Focal Onset | 1 | CTD_human |
Tgene | SOD2 | C0750901 | Alzheimer Disease, Early Onset | 1 | CTD_human |
Tgene | SOD2 | C0750974 | Brain Tumor, Primary | 1 | CTD_human |
Tgene | SOD2 | C0750977 | Recurrent Brain Neoplasm | 1 | CTD_human |
Tgene | SOD2 | C0750979 | Primary malignant neoplasm of brain | 1 | CTD_human |
Tgene | SOD2 | C0751019 | Carotid Circulation Transient Ischemic Attack | 1 | CTD_human |
Tgene | SOD2 | C0751020 | Transient Ischemic Attack, Vertebrobasilar Circulation | 1 | CTD_human |
Tgene | SOD2 | C0751021 | Crescendo Transient Ischemic Attacks | 1 | CTD_human |
Tgene | SOD2 | C0751022 | Brain Stem Ischemia, Transient | 1 | CTD_human |
Tgene | SOD2 | C0751056 | Non-epileptic convulsion | 1 | CTD_human |
Tgene | SOD2 | C0751110 | Single Seizure | 1 | CTD_human |
Tgene | SOD2 | C0751123 | Atonic Absence Seizures | 1 | CTD_human |
Tgene | SOD2 | C0751316 | Acquired Meningomyelocele | 1 | CTD_human |
Tgene | SOD2 | C0751406 | Post-Traumatic Osteoporosis | 1 | CTD_human |
Tgene | SOD2 | C0751494 | Convulsive Seizures | 1 | CTD_human |
Tgene | SOD2 | C0751495 | Seizures, Focal | 1 | CTD_human |
Tgene | SOD2 | C0751496 | Seizures, Sensory | 1 | CTD_human |
Tgene | SOD2 | C0751651 | Mitochondrial Diseases | 1 | CTD_human |
Tgene | SOD2 | C0751845 | Middle Cerebral Artery Embolus | 1 | CTD_human |
Tgene | SOD2 | C0751846 | Left Middle Cerebral Artery Infarction | 1 | CTD_human |
Tgene | SOD2 | C0751847 | Embolic Infarction, Middle Cerebral Artery | 1 | CTD_human |
Tgene | SOD2 | C0751848 | Thrombotic Infarction, Middle Cerebral Artery | 1 | CTD_human |
Tgene | SOD2 | C0751849 | Right Middle Cerebral Artery Infarction | 1 | CTD_human |
Tgene | SOD2 | C0751851 | Arsenic Encephalopathy | 1 | CTD_human |
Tgene | SOD2 | C0751852 | Arsenic Induced Polyneuropathy | 1 | CTD_human |
Tgene | SOD2 | C0752347 | Lewy Body Disease | 1 | CTD_human |
Tgene | SOD2 | C0848676 | Subfertility, Male | 1 | CTD_human |
Tgene | SOD2 | C0860207 | Drug-Induced Liver Disease | 1 | CTD_human |
Tgene | SOD2 | C0878544 | Cardiomyopathies | 1 | CTD_human |
Tgene | SOD2 | C0917731 | Male sterility | 1 | CTD_human |
Tgene | SOD2 | C0917805 | Transient Cerebral Ischemia | 1 | CTD_human |
Tgene | SOD2 | C0920563 | Insulin Sensitivity | 1 | CTD_human |
Tgene | SOD2 | C0948089 | Acute Coronary Syndrome | 1 | CTD_human |
Tgene | SOD2 | C0949855 | Electron Transport Chain Deficiencies, Mitochondrial | 1 | CTD_human |
Tgene | SOD2 | C0949856 | Oxidative Phosphorylation Deficiencies | 1 | CTD_human |
Tgene | SOD2 | C0949857 | Mitochondrial Respiratory Chain Deficiencies | 1 | CTD_human |
Tgene | SOD2 | C1134719 | Invasive Ductal Breast Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C1168401 | Squamous cell carcinoma of the head and neck | 1 | CTD_human |
Tgene | SOD2 | C1262760 | Hepatitis, Drug-Induced | 1 | CTD_human |
Tgene | SOD2 | C1266042 | Chromophobe Renal Cell Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C1266043 | Sarcomatoid Renal Cell Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C1266044 | Collecting Duct Carcinoma of the Kidney | 1 | CTD_human |
Tgene | SOD2 | C1269683 | Major Depressive Disorder | 1 | CTD_human |
Tgene | SOD2 | C1306837 | Papillary Renal Cell Carcinoma | 1 | CTD_human |
Tgene | SOD2 | C1383860 | Cardiac Hypertrophy | 1 | CTD_human |
Tgene | SOD2 | C1527168 | Bonnevie-Ullrich Syndrome | 1 | CTD_human |
Tgene | SOD2 | C1527231 | Adrenomyeloneuropathy | 1 | CTD_human |
Tgene | SOD2 | C1527335 | Transient Ischemic Attack, Anterior Circulation | 1 | CTD_human |
Tgene | SOD2 | C1527390 | Neoplasms, Intracranial | 1 | CTD_human |
Tgene | SOD2 | C1571983 | Involutional paraphrenia | 1 | CTD_human |
Tgene | SOD2 | C1571984 | Psychosis, Involutional | 1 | CTD_human |
Tgene | SOD2 | C1623038 | Cirrhosis | 1 | CTD_human |
Tgene | SOD2 | C1855119 | Methylmalonic aciduria | 1 | CTD_human |
Tgene | SOD2 | C1859317 | Cataract and cardiomyopathy | 1 | CTD_human |
Tgene | SOD2 | C2711227 | Steatohepatitis | 1 | CTD_human |
Tgene | SOD2 | C2713442 | Polyposis, Adenomatous Intestinal | 1 | CTD_human |
Tgene | SOD2 | C2713443 | Familial Intestinal Polyposis | 1 | CTD_human |
Tgene | SOD2 | C2931822 | Nasopharyngeal carcinoma | 1 | CTD_human |
Tgene | SOD2 | C3495874 | Nonepileptic Seizures | 1 | CTD_human |
Tgene | SOD2 | C3658290 | Drug-Induced Acute Liver Injury | 1 | CTD_human |
Tgene | SOD2 | C3714618 | Primary Hyperthyroidism | 1 | CTD_human |
Tgene | SOD2 | C4048158 | Convulsions | 1 | CTD_human |
Tgene | SOD2 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
Tgene | SOD2 | C4279912 | Chemically-Induced Liver Toxicity | 1 | CTD_human |
Tgene | SOD2 | C4316903 | Absence Seizures | 1 | CTD_human |
Tgene | SOD2 | C4317109 | Epileptic Seizures | 1 | CTD_human |
Tgene | SOD2 | C4317123 | Myoclonic Seizures | 1 | CTD_human |
Tgene | SOD2 | C4505436 | Generalized Absence Seizures | 1 | CTD_human |
Tgene | SOD2 | C4551650 | Esophageal Stricture | 1 | CTD_human |
Tgene | SOD2 | C4721453 | Peripheral Nervous System Diseases | 1 | CTD_human |
Tgene | SOD2 | C4721845 | Marfan Syndrome, Type I | 1 | CTD_human |